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 ABSTRACT 
 
THE ROLE OF CANNABINOIDS AND CANNABINOID RECEPTORS IN ENTERIC 
NEURONAL SURVIVAL 
By Yan Li 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University 2009  
Major Director: John R. Grider,  
Professor, Department of Physiology and Biophysics 
 
The Endocannabinoid system has been found in the gastrointestinal tract, where it plays 
an important role in gut under both physiological and pathological conditions. Although 
the major effects of cannabinoids in the gut are mediated through effects on enteric 
neurons, the role of cannabinoids in the enteric nervous system is poorly understood. In 
the present study, we have used the primary cultures of myenteric ganglia and a newly 
developed fetal enteric neuronal cell line to identify whether the endocannabinoid, 
anandamide, affects ganglionic and neuronal survival and the pathways involved.  
Anandamide had a biphasic effect on ganglionic survival, increasing survival at low 
concentrations (1nM-0.1uM) and decreasing survival at high concentrations (1-10uM). 
Maximal survival (68% increase in number of ganglia surviving) occurred at 0.1uM and 
the ED50 was 3nM. This effect on promoting survival was inhibited by the CB1 
antagonist AM251 (1uM) and by AraC (10uM), but not the CB2 antagonist AM630 
xvi 
(1uM). AM630 (1uM) significantly blocked the decreased survival induced by high 
concentration anandamide (10uM). The enteric glia was involved in anandamide-induced 
ganglion survival. Anandamide had no effect on the number of neurons/ganglion in the 
presence of enteric glia, but decreased the number of neurons/ganglion by 15-20% in 
absence of enteric glia. This effect was partially reversed by CB1 antagonist, AM251 
(1uM) (20%-145% at 1nM-10uM) and by CB2 antagonist AM630 (1uM) (40%-185% at 
1nM-10uM). In the fetal enteric neural cell line (IM-FEN), anandamide decreased enteric 
neuronal survival in a concentration-dependent manner at both 39 and 33 degree (11-45% 
and 10-22%decrease in survival at 1nM-10uM, respectively). Coculture of astrocytes 
with the enteric neuronal cells was not able to reverse anandamide-mediated neuronal 
death. Immunocytochemistry and western blot confirmed that the presence of both CB1 
and CB2 receptors in enteric neurons (primary cultures and IM-FEN) and glia (primary 
cultures). In addition, the PLC-beta inhibitor U73122 (1uM) inhibited anandamide 
induced ganglia survival significantly. Anandamide also induced increased expression of 
phospho-P44/42MAPK (13-48% at 1nM-10uM) and phospho-AKT (1-28% at 1 nM-
10uM) in IM-FEN. 
We conclude that anandamide has a differential effect on survival of enteric ganglia and 
neurons. It promotes ganglionic and neuronal survival by CB1 receptors in the presence 
of glia and this involves the PLC-beta pathway. Conversely, anandamide promotes 
neuron death in absence of glia as a result of effects on both the MAPK and PI-3K/AKT 
pathways. Since the endocannabinoid system is upregulated in inflammatory bowel 
diseases, these effects may play a role in the pathogenesis of the response to 
inflammation as well as the recovery and reinnervation of the gut following the acute 
 
xvii 
phase of inflammation. The further significance of this work could contribute to 
developing new therapeutic methods for treatment of inflammatory bowel disease and 
related symptoms in clinic practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Introduction 
 
Enteric nervous system 
The gut is innervated by both extrinsic (parasympathetic and sympathetic) and intrinsic 
enteric nervous system (ENS). The extrinsic parasympathetic inputs originate in the 
dorsal motor nucleus of the vagus, which controls primarily the motility of the esophagus 
and stomach, and the sacral parasympathetic nucleus, which contributes to control of 
motility of the distal colon and rectum. The sympathetic adrenergic fibers from the 
prevertebral ganglia innervate the secretomotor neurons, presynaptic cholinergic nerve 
endings, submucosal blood vessels, and the sphincters of the GI tract.   
The enteric nervous system consists of the ganglia which are grouped into two plexuses: 
the myenteric plexus (Auerbach’s plexus), located between the outer longitudinal and the 
inner circular muscle layers, and submucosal plexus (Meissner plexus), located between 
the circular muscle and the muscularis mucosa (Figure 1). The myenteric plexus 
primarily provides motor innervation to the muscle layers and some secreomotor 
innervation to the mucosa. The submucosal plexus mainly regulates mucosal secretion 
and blood flow (1). 
 
Enteric neurons 
The enteric ganglia consist of enteric neurons and glia. Enteric neurons are classified into 
different categories based on their histochemical, electrophysiologic and functional 
1 
2 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of the gut wall. The GI tract can be divided into: mucosa, submucosa, 
circular muscle layer, longitudinal muscle layer and serosa from inside to outsider in 
order. Myenteric plexus (Auerbach’s plexus) is located between the inner circular muscle 
layers and outer longitudinal, and submucosal plexus (Meissner plexus), located between 
the circular muscle and the muscularis mucosa. Adapted from John B. Furness136
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4 
properties. They are functionally classified into intrinsic primary afferent neurons 
(IPANs), interneurons, motor neurons, secretomotor neurons, and vasomotor neurons.  
The IPANs are located in both the myenteric and submucosal plexuses. AH/Dogiel Type 
II neurons have smooth oval cell bodies with multiple processes (Dogiel Type II) and 
prolonged hyperpolarization after action potential, which have been found in the 
myenteric and submucosal plexuses of the small and large intestines. There is 
considerable evidence that AH neurons behave as intrinsic sensory neurons as they 
respond to a variety of chemical and mechanical stimuli applied to the mucosa and to 
muscle stretch and contraction (2-9). Local chemical and mechanical stimulation of the 
mucosa activate IPANs in part via release of serotonin from enterochromaffin cells, and 
then serotonin activate terminals of IPANs via 5-HT4 receptors (10,11). 
The other electrophysiological type of neurons are S/Type I neurons, which have a 
variety of cell shapes and are uniaxonal. Fast excitatory postsynaptic potential (FEPSPs) 
can be readily evoked in S neurons. S neurons comprise the motor neurons and most of 
the interneurons. There are some mechanosensitive interneurons found in the guinea pig 
distal colon where they respond directly to changes in muscle length (circumferential 
stretch and longitudinal stretch), rather than muscle tone or tension (12). 
The peristaltic reflex is a coordination of IPANs, interneurons and excitatory and 
inhibitory motoneurons which allows the normal propulsion of the contents of the gut. 
The ascending excitatory reflex involves myenteric motor neurons that utilize Ach and 
substance P and elicit contraction of the smooth muscle located orally to the site of 
stimulation. The descending inhibitory reflex involves inhibitory motor neurons that 
utilize NO, VIP and PACAP and elicit relexation of the smooth muscle located anally to 
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the site of stimulation (13). 
 
Enteric glia 
The most abundant cells in the ENS are enteric glial cells that lie adjacent to the neurons 
in the enteric ganglia and envelop both their cell bodies and axon bundles (9). They were 
also found in the interconnecting nerve strands of the ganglionated and in all non-
ganglionated plexuses, submucosal blood vessels and the mucosal epithelium (14-20). 
The enteric glia has an important role in regulating barrier function of the intestinal 
epithelium (21-22) and neurochemical coding of enteric neurons (23). Proinflammatory 
cytokines induced neurotrophic factors glial-derived neurotrophic factor (GDNF) and 
nerve growth factor (NGF) expression in enteric glia, suggesting their active role in 
inflammation (24-25). Recently, the communication between neuron and glia has been 
found in both guinea pig and mice where neuron released ATP could elicit a Ca2+ 
response in enteric glia (26-27). In addition, lipopolysaccharides (LPS) enhanced the 
action of bradykinin in enteric neurons via secretion of interleukin-1β (IL-1β) from 
enteric glial cells in neonatal rats (28). 
 
Interstitial cells of Cajal 
Interstitial cells of Cajal (ICC) are a non-neural cell type of similar mesenchymal origin 
to the muscle, which have been found throughout the gastrointestinal tract from the 
esophagus to the anus in a wide variety of species including humans. Morphological and 
physiological studies indicate that ICC play key roles in peristaltic movement as 
pacemaker cells and as mediators of neural activity to the gastrointestinal musculature 
 
6 
(29). Each part of the digestive tract shows a specific distribution of ICC. 
ICC show a highly branched morphology and form unique networks including myenteric 
ICC at the level of the myenteric plexus (ICC-MY), intramuscular ICC in the 
musculature (ICC-IM), ICC in deep muscular plexus layer in the small intestine (ICC-
DMP) and submucosal ICC at the submucosal surface of the circular muscle layer (ICC-
SM). ICC-MY and ICC-SM serve as electrical pacemakers, generating slow waves, 
whereas ICC-IM and ICC-DMP are mediators of enteric motor neurontransmission so 
that neural influence is superimposed on the rhythmic activity of the muscle generated by 
ICC. ICC are primarily innervated by nitrergic (nNOS-containing) enteric neurons (30). 
However, inhibitory neurotransmitters can reach smooth muscle cells without hindrance 
when ICC are absent in fundus of stomach (31). In the small intestine, electrical slow 
waves are generated by ICC-MY, whereas slow waves in the colon originate in ICC-SM. 
The reason could be due to that ICC-SM form a tightly coupled network that is able to 
generate and propagate slow waves in the colon; in contrast, Ca2+ transients in ICC-MY 
which are normally not synchronized, have a similar duration and frequency as myenteric 
potential oscillations (MPOs). Like MPOs, their activity is inhibited by nitrergic nerves 
and synchronized by excitatory nerves (32). 
 
Endocannabinoid system 
Endocannabinoids 
Cannabinoids have a long history of consumption for recreational and medical reasons. 
Δ9-tetrahydrocannabinol (Δ9-THC) is the primary active constituent of the hemp plant 
Cannabis sativa, which is mediated by at least two types of receptors (CB1 and CB2 
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receptors). Both of them are coupled to Gi/o proteins  (33,34). The endogenous ligands for 
these receptors are also detected in mammalian tissues which are eicosanoids including 
arachidonoylethanolamide (anandamide) and 2-arachidonoyl glycerol (2-AG) (35). 
Endocannabinoids are generated and released on demand after cellular depolarization in a 
calcium-dependent manner (36) or by activating dendritic metabotropic glutamate 
receptors (mGluRs) in a calcium-independent manner (37,38). 
Different pathways are involved in the synthesis and release of anandamide and 2-AG. 
Anandamide is formed by the cleavage of a phosphatidylethanolamine (NAPE), which is 
catalysed by a specific phospholipase D (PLD) (39) (Figure2). 2-AG is mainly 
synthesized by the receptor-dependent activation of phosphatidylinositol-specific 
phospholipase C (PLC) (40,41). Once anandamide and 2-AG are formed, they target the 
CB1 receptors in the same cell where they were formed (42) or they can be released to 
the presynaptic terminals, acting as the retrograde synaptic messengers (43) in the brain.  
Endocannabinoids are removed from their sites of action by tissue uptake processes 
which could be involved in endocannabinoid membrane transporter (EMT) and 
metabolized mainly by fatty acid amide hydrolase (FAAH) for anandamide or 
monoacylglycerol lipase (MAGL) for 2-AG (35). 
 
CB1 and CB2 receptors 
CB1 receptors are found predominantly at central and peripheral nerve terminals and 
expressed at high levels in the hippocampus, cortex, cerebellum, and basal ganglia (44-
46). CB2 receptors occur mainly on immune cells, one of their roles being to modulate 
cytokine release (47). Recently GPR55, an orphan G protein-coupled receptor, 
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Figure 2. A schematic representation of the putative pathway for anandamide 
biosynthesis 
N-acyl transferase (NAT), using phosphatidylcholine (PC) and phosphatidylethanolamine 
(PE) as substrates, transfers a fatty acyl chain from the sn-1 position of a glycerolipid to 
PE in a calcium-dependent fashion, yielding N-arachidonyl phosphatidylethanolamine 
(NAPE). The formation of anandamide (AEA) is catalyzed by a calcium-dependent 
NAPE phospholipase D (NAPE PLD). Adopted from Ekaterina A. Placzek137
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10 
has been proposed as a new member of the cannabinoid receptors (48). 
Endocannabinoids exhibit different binding properties and intrinsic activity at CB1 and 
CB2 receptors. Anandamide behaves as a partial agonist at both CB1 and CB2 receptors, 
but has higher affinity for the CB1 receptor (49,50) .The intrinsic activity of anandamide 
at CB1 receptors is 4–30 fold higher than at CB2 receptors. However, 2-AG is a complete 
agonist at both CB1 and CB2 receptors and it exhibits less affinity than anandamide for 
both CB1 and CB2 receptors (40,49). 
Taken together, endocannabinoids, their synthetic and degradative enzymes, eCB 
transporters, and cannabinoid receptors constitute the ‘endocannabinoid system’. 
 
Pharmacology of cannabinoids 
The mainly used cannabinoid reagents are summarized in Table1 and the structure of 
typical cannabinoid agonists shown in Figure3. 
 
Cannabinoid receptor agonists 
According to the International Union of Pharmacology, cannabinoid agonists can be 
divided into classical cannabinoids, non-classical cannabinoids, aminoalkylindoles and 
eicosanoids. Classical cannabinoids are tricyclic dibenzopyran derivatives that are either 
compounds occurring naturally in the plant C. sativa, or synthetic analogues of these 
compounds. The most representative forms are Δ9-THC, a partial agonist at both the CB1 
and CB2 receptors and the main psychoactive constituent of Cannabis, along with 11-
hydroxy-Δ 8-THC-dimethylheptyl (HU-210), a synthetic compound that displays the 
highest potency at the CB1 receptor (49). Non-classical cannabinoids are synthetic THC  
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Table 1. The mainly used cannabinoid reagents (35,38) 
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Main cannabinoid agonists and antagonists  
Ligand  Chemistry 
Non-selective cannabinoid receptor agonists 
Anadamide 
2-AG 
HU210 
CP55,940 
Δ9-THC 
R-(+)-WIN-55,212-2 
 
Eicosanoid derivative, endogenous ligand 
Eicosanoid derivative, endogenous ligand 
Dibenzopyrane derivative, synthetic 
Analog of Δ9-THC lacking a pyran ring, 
synthetic 
Dibenzopyrane derivative, plant-derive 
Aminoalkylindole, synthetic 
 
Selective CB1 receptor agonists  
ACEA  
Noladin ether  
R(+)-methanadamide 
ACPA 
O-1812 
 
Eicosanoid, synthetic 
Lipid-ether, endogenous ligand 
Eicosanoid, synthetic 
Eicosanoid, synthetic 
Eicosanoid, synthetic 
 
Selective CB2 receptor agonists 
JWH-015 
JWH-133 
L-759633 
L-759656 
 
Aminoalkylindole, synthetic 
Analog of Δ9-THC, synthetic 
Analog of Δ9-THC, synthetic 
Analog of Δ9-THC, synthetic 
 
Selective CB1 receptor antagonists  
SR141716A 
AM281 
SR147778  
LY320135 
LH-21 
AM251 
 
Diarylpyrazole, synthetic 
Diarylpyrazole, synthetic 
Diarylpyrazole, synthetic 
Substituted benzofuranes, synthetic 
Triazole derivatives, synthetic 
Diarylpyrazole, synthetic 
 
Selective CB2 receptor antagonists 
SR144528 
AM630 
 
Diarylpyrazole, synthetic 
Aminoalkylindoles, synthetic 
 
Uptake inhibitors  
AM404 
UCM707 
AM1172 
 
Eicosanoid derivatives, synthetic 
Eicosanoid derivatives, synthetic 
Eicosanoid derivatives, synthetic 
 
FAAH inhibitors 
OL-135 
URB597 
PIA 
 
Alpha heterocycles, syntheric 
O-arylcarbamate, synthetic 
Eicosanoid derivatives, synthetic 
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Figure 3. The structure of typical cannabinoid agonists (191). 
Δ9-THC is a tricyclic dibenzopyran derivatives from plant Cannabis. CP-55940 is a 
synthetic THC analogue that lack the dihydropyran ring. R-(+)-WIN-55,212–2 is the 
represent form of aminoalkylindoles. Endocannabinoids anandamide and 2-AG are 
eicosanoids. 
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analogues that lack the dihydropyran ring. The most representative form is the Pfizer 
compound CP-55940, a potent and complete agonist at both the CB1 and CB2 receptors, 
which was used to characterize the CB1 receptor for the first time (44,51). 
Aminoalkylindoles were the first non-cannabinoid molecules that displayed 
cannabimimetic activity (52). R-(+)-WIN-55,212–2 is the most representative form, and it 
behaves as a complete agonist at both the CB1 and CB2 receptors, with higher intrinsic 
activity at the CB2 receptor. Eicosanoids are the prototypic endocannabinoids, of which 
anandamide and 2-AG are the most representative compounds. Based on the structure of 
anandamide, minor chemical changes have led to the development of the first generation 
of CB1-selective agonists, of which R(+)- methanandamide and arachidonyl-2’-
chloroethylamide (ACEA) are the most representative forms (50). 
 
Cannabinoid receptor antagonists 
Several compounds have been developed as cannabinoid receptor antagonists such as 
diarylpyrazoles, substituted benzofuranes, aminoalkylindoles and triazole derivatives 
(53). Diarylpyrazoles include both the first CB1 receptor antagonist SR 141716A (54) 
and the first CB2 receptor antagonist SR 144528. A CB2 receptor antagonist, AM 630, 
belong to aminoalkylindoles (49). 
 
Uptake blockers and inhibitors of fatty acid amide hydrolase 
Based on the structure of anandamide, a series of eicosanoid derivatives that have the 
ability to block anandamide transport have been synthesized (53). The first and best 
studied transport inhibitor is AM 404 (55). The administration of AM 404 results in the 
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accumulation of anandamide and potentiates the effects of exogenously administered 
anandamide. The compound AM 404 can be degraded by FAAH and behaves as an 
agonist of vanilloid receptors. UCM 707 (56,57) and AM 1172 (58) have also been 
shown to efficiently block endocannabinoid uptake. In addition, OL-135 has been shown 
to possess very high potency and selectivity to reversibly inhibit FAAH activity in vivo 
and in vitro (59). 
 
Endocannabinoid signaling 
CB1 signaling transduction pathways 
The CB1 cannabinoid receptor is a member of the rhodopsin subfamily of GPCRs, which 
is coupled through Gi/o proteins, negatively to adenylate cyclase and positively to 
mitogen-activated protein kinase. CB1 receptor stimulation is also coupled to PLC 
activation, in turn increasing levels of InsP3 for the induction of Ca2+ release from 
internal stores (60). CB1 receptors can also interact with Gs to activate adenylate cyclase 
under conditions of PTX treatment that prevents the receptor interaction with Gi/o 
proteins (61,62) and in human embryonic kidney (HEK) 293 cells transfected with CB1 
and D2 receptors (63). 
In addition, CB1 receptors are coupled through Gi/o proteins to certain ion channels, 
activating G-protein-coupled inward rectifier K+ (64) and A-type outward potassium 
channels (65), and inhibiting D-type outward potassium channels (66), N-type and P/Q 
type calcium channels (67,68), L-type Ca2+ currents (69). Regardless of the specific 
target, the actions of cannabinoids are predicted to have an inhibitory effect on neurons in 
most cases. Inhibition of presynaptic calcium channels reduces neurotransmitter release, 
whereas activation of postsynaptic K+ channels suppresses action-potential firing (70). 
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CB2 signaling transduction pathways 
Similar to CB1, CB2 receptors activation can inhibit adenylyl cyclase (71,72) and 
activate p42/p44 MAP kinase activity, through their ability to couple to Gi/o proteins in 
CHO cells and HL-60 cells (73,74). Treatment of human prostate epithelial PC-3 cells 
with cannabinoids activated the PI3K/PKB pathway, which in turn induced translocation 
of Raf-1 to the membrane and phosphorylation of p42/p44 MAP kinase through CB2 
receptor (75). In addition, anandamide could initiate a rise in [Ca2+]i in calf pulmonary 
endothelial cells through activation of PLC , which was sensitive to inhibition by the CB2 
antagonist (76), suggesting CB2 receptor was involved in this process. 
However, in contrast to CB1, CB2 receptor stimulation was not found to modulate ion 
channel function in AtT-20 cells transfected with CB2 (77) and Xenopus oocytes 
transfected with CB2 and GIRK1/4 (78). 
 
Cannabinoids in gut 
Cannabinoid receptors in gastrointestinal tract 
The presence of cannabinoid receptors in the gastrointestinal tract has been demonstrated 
by anatomical and functional evidences, which was summarized in table 2. 
CB1 receptors were detected in enteric nervous system of different species, including 
mice, rats, guinea pigs, pigs and humans by immunohistochemistry (79-88), where it is 
frequently colocalized to ChAT neurons. Interestingly, they were not coexpressed in 
NOS-positive neurons in pig and mice (79,84,85). 
CB2 receptor expression was present on plasma cells in the lamina propria and 
macrophages in human colon (88). Later it was detected in enteric neurons 
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Table 2. Localization of cannabinoid CB1 and CB2 receptors in the gastrointestinal tract. 
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Localization of cannabinoid CB1 and CB2 receptors in the gastrointestinal tract. 
Animal 
species  
Region of the gut  Technique Findings 
Ileum IHC All CB1 colocalized with ChAT 
CB1 occasionally associated with SP 
CB1 co-localised with opioid receptor 
CB1 not with VIP or NOS-positive neurons 
Pig (22)
Colon IHC Most CB1 colocalized with ChAT  
CB1/ChAT-neurones frequently expressed SP in 
submucosal plexuses 
CB1 not with VIP or NOS-positive neurons  
Guinea 
pig (21) 
Myenteric plexus  IHC Sensory, interneuronal and motoneuronal cell 
bodies and nerve fibres expressed CB1 
Guinea 
pig (37)
Submucosal plexus 
of ileum 
IHC CB1 colocalized with VIP and NPY  
CB1 colocalized with TRPV1 on paravascular 
nerves and fibers in the submucosal plexus  
Rat (33) Stomach fundus, 
corpus and antrum. 
IHC CB1 colocalized with CHAT in neural elements 
innervating smooth muscle, mucosa and 
submucosal blood vessels 
CB2 not observed 
Rat (21) Whole mounts of  
myenteric 
preparations 
IHC CB1 expressed on cholinergic sensory, 
interneuronal, and motor neurons 
Immunoblotting CB1 high in stomach and colon, but not in the 
pyloric valve  
IHC CB1 in ganglia subadjacent to the gastric 
epithelium and in the smooth muscle layers of 
both the small and large intestine. 
Mice (24) All regions 
Radioligand 
binding 
[3H]CP 55,940 specific binding in the small 
intestine 
Mice 
(31,32)
Colon IHC CB1 in neurons within myenteric and 
submucosal ganglia and nerve fibers  
CB1 frequently colocalized to a subpopulation 
of CHAT neurons and fiber bundles in the 
myenteric plexus 
CB1-R and NOS not overlap in myenteric or 
submucosal neurons and fibers 
Human 
(38)
Stomach and colon RT-PCR CB1 mRNA detected 
Human 
(39)
Colon IHC CB1 in all major ganglionated nerve plexuses, 
predominantly within myenteric ganglia.  
CB1 in the submucosal plexus, mucosa and in 
serosa 
CB1 coexpressed with CHAT in myenteric 
neurones  
CB1-R/ChAT nerve fibers in CM layer and 
submucosa 
Human 
(40)
Colon  IHC CB1 evident in epithelium, smooth muscle, and 
the submucosal myenteric plexus 
CB1 on plasma cells in the lamina propria 
CB2 on plasma cells in the lamina propria and 
macrophages 
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morphologically and functionally (89). In addition, CB2R has been demonstrated to 
reside on a wide variety of peripheral blood leukocytes and spleen cell populations (90) 
and to a greater extent than seen for CB1R in the same cell types that include B cells, T 
cells, NK cells, splenic macrophages, dendritic cells, and neutrophils (91-93). 
 
Physiological role of cannabinoids and CB receptors in GI 
Activation of CB1 receptor has been reported to inhibit pentagastrin-induced gastric acid 
secretion (82,94) at peripheral level. I.c.v. injection of anandamide stimulated gastric acid 
secretion, however, the response was inhibited by an antagonist of TRPV1 and in the 
capsaicin-treated rats, but not by an antagonist of cannabinoid receptors (95). It suggested 
that anandamide could activate TRPV1 in the brain and stimulates gastric acid secretion 
in rats. 
Generally cannabinoids mediate an inhibitory effect on GI motility. Functional studies 
have shown that cannabinoids inhibited (via CB1 activation) lower oesophageal sphincter 
relaxation in dogs (96) and ferrets (97) which could be mediated by modulation of vagal 
activity at peripheral and central levels. Intravenous Δ9-THC administration slows down 
the rate of gastric emptying of solid food in humans (98). In addition, several cannabinoid 
agonists inhibited gastric and intestinal motility in rats and mice through CB1 activation 
(99-101). The antipropulsive effects of cannabinoids could be the result of inhibition of 
both excitatory cholinergic/tachykininergic and inhibitory VIPergic motor neurons which 
mediate ascending contraction and descending relaxation respectively, as well as 
inhibition of the intrinsic sensory CGRP-containing neurons which initiate the peristaltic 
reflex underlying propulsive activity (102). 
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Pathological role of cannabinoids and CB receptors in GI (Summarized in table 3) 
Inflammation 
Inflammation represents the response of body tissue to immune reactions, injury, or 
ischemic damage (103). It can be divided into two basic patterns: acute and chronic 
(104,105). Acute inflammation is of relatively short duration, lasting from a few minutes 
to several days, and is characterized by the exudation of fluid and plasma components 
and emigration of leukocytes, predominantly neutrophils, into the extravascular tissues. 
Chronic inflammation is of a longer duration, lasting for days to years, and is associated 
with the presence of lymphocytes and macrophages, proliferation of blood vessels, 
fibrosis, and tissue necrosis (103). 
Acute inflammation is the early (almost immediate) reaction of local tissue and their 
blood vessels to injury. It typically occurs before the immune response becomes 
established and is aimed primarily at removing the injurious agent and limiting the extent 
of tissue damage. Acute inflammation involves two major components: the vascular and 
cellular stages (104-106). The vascular, or hemodynamic, changes are initiated by a 
momentary constriction of small blood vessels in that area, which is followed rapidly by 
vasodilatation of the arterioles and venules that supply the area. Accompanying this 
response is an increased permeability of vessels in the microcirculation, with the 
outpouring of a protein-rich fluid (exudate) into the extravascular spaces. The cellular 
stage of acute inflammation is marked by movement of leukocytes into the area of injury. 
Two types of leukocytes participate in the acute inflammatory response-granulocytes and 
monocytes (103). 
A rapid response also requires the release of chemical mediators from tissue cells (mast 
 
22 
 
 
 
 
 
 
 
 
 
 
Table 3. The role of cannabinoids and cannabinoid receptors in inflammation of 
gastrointestinal tract. 
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The role of cannabinoids and cannabinoid receptors in inflammation of gastrointestinal tract 
Experimental models /animal 
species 
Functions 
Ileum 
Rat (63) Anandamide and 2-AG caused ileitis via VR1 and SP release 
WIN 55,212-2, HU 210 and PEA had no affect 
Indomethacin-induced small 
intestinal injury (rat) (66)
Oral CB1 antagonist prevented ulcers and the rise in TNF-α levels 
and intestinal MPO activity.  
Oral CB2 antagonist prevented intestinal ulcers only 
(+)-WIN 55, 212-2 and CP 55940 had no effects 
LPS-induced ileitis (rat) (66) Oral CB1 antagonist prevented the increase of TNF-a levels 
CB2 antagonist had no effect 
LPS-induced ileitis (WT and CB1-
/- mice) (66)
Oral CB1 antagonist inhibited the increase of TNF-a in WT, but not 
in CB1-/- mice 
CB2 antagonist had no effect in both WT and CB1-/- mice 
Croton oil-induced intestinal 
inflammation (mice) (68)
Cannabinoids (i.p.) were more active in delaying intestinal motility 
via peripheral CB1 receptors 
LPS-induced ileitis (rat) (70) CB2 agonist inhibits intestinal motility via cyclooxygenase, IL-1β 
and eNOS. 
Colon 
Intracolonic OM induced acute 
colitis (mice) (75)
CB1 and CB2 agonists (i.p.) attenuate OM colitis 
CB1R upregulated in endothelium and myenteric ganglia 
CB2R-positive cells were evident 
DSS induced colitis (mice) (75) CB1 and CB2 agonists attenuated DSS colitis 
CB1R upregulated in myenteric ganglia 
CB2R immunoreactivity evident 
DNBS and DSS colitis (WT and 
CB1-/- mice) (77)
DNBS and DSS induced stronger inflammation in CB1-/- mice  
Cannabinoid agonist HU210 or FAAH-/- protect against DNBS 
colitis  
Myenteric neurons expressing CB1 increased in DNBS colitis 
DNBS colitis (CB1−/−, TRPV1−/− 
and WT mice) (78)
Rhythmic action potentials in colonic circular smooth muscle cells 
of CB1−/− and TRPV1−/− mice 
IJP in CB1−/− mice was longer 
DNBS colitis (mice) 
TNBS colitis (rat) 
Ulcerative colitis (human) (81)
Elevation of anandamide 
Inhibitor of anandamide reuptake (VDM11) abolished 
inflammation 
Inhibitor of FAAH (AA-5-HT) less efficacious at attenuating colitis 
TNBS colitis (rat) (82) CB1 and CB2 agonists (i.p.) reduce basal sensitivity and TNBS 
colitis-induced hypersensitivity to CRD 
CB1 antagonist enhanced colitis-induced hyperalgesia. 
Rats and mice (83) probiotic bacteria NCFM induced the expression of MOR1 (m-
opioid receptors) and CB2 in epithelial cells of colonic section 
Butyrate enemas elicited colonic 
hypersensitivity (rat) (83)
NCFM-induced analgesia was inhibited by CB2-selective 
antagonist 
Human colonic epithelial cell lines 
(40)
Cannabinoids enhanced epithelial wound closure by the CB1 
receptor 
Inflammatory bowel disease 
(human) (40)
CB2 immunoreactivity in the epithelium of colonic tissue 
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cells and macrophages) that are prepositioned in the tissue (107). Mast cells are 
particularly prevalent along mucosal surface of the lung and gastrointestinal tract and the 
dermis of the skin. This distribution places the mast cell in a sentinel position between 
environmental antigens and the host for a variety of acute and chronic inflammation 
conditions (105). 
Although inflammation is precipitated by injury, its signs and symptoms are produced by 
chemical mediators that are derived either from the plasma or from cells. Plasma-derived 
mediators of inflammation include the kinins, the products of the coagulation/fibrinolysis 
system, and the proteins of the complement system. Cell-derived mediators include 
histamine and serotonin, arachidonic acid metabolites, platelet-activating factors, 
cytokines, and nitric oxide (103). 
Characteristic of chronic inflammation is an infiltration by mononuclear cells 
(macrophages) and lymphocytes instead of the neutrophils commonly seen in acute 
inflammation. Chronic inflammation also involves the proliferation of fibroblasts instead 
of exudates (103). 
 
Role in ileum inflammation (Figure 4) 
Cannabinoids in gut inflammation have been widely studied in experimental animal 
models. Endocannabinoids cause inflammation in the rat ileum via capsaicin VR1 
receptor-mediated SP release from primary sensory nerves in the intestinal mucosa. 
Toxin A increased tissue concentrations of anandamide and 2-AG in the ileum, and these 
effects were enhanced after pretreatment with inhibitors of fatty acid amide hydrolase, 
suggesting endocannabinoids may mediate the inflammatory effects of toxin A (108). 
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Figure 4. Role of cannabinoids and cannabinoid receptors in ileitis. 
Continuous arrows denote stimulation and induction. Broken arrows denote inhibition. 
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Figure 4. Roles of cannabinoids and cannabinoid receptors in ileitis. 
Continuous arrows denote stimulation and induction. Broken arrows denote inhibition. 
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Substantial studies have shown that cannabinoid antagonists play a protective role in 
inhibition of mucosa damage via both CB1 and CB2 receptors. CB1 antagonists dose-
dependently prevented indomethacin-induced ulcers, the rise in TNF-α levels and 
intestinal MPO activity. CB2 antagonists prevented intestinal ulcers only. In addition, 
CB1 antagonists prevented LPS-induced increase of TNF-α levels in rat and wide-type 
mice plasma, but not in CB1 receptor knockout mice (109), suggesting that the anti-
inflammatory role of CB1 antagonists was mainly mediated by cytokine TNF-α. 
Cannabinoids (i.p.) were more active in delaying intestinal motility in croton oil-treated 
mice than in control mice which was reversed by CB1 antagonist, indicating an 
involvement of CB1. Croton oil-induced intestinal inflammation was associated with an 
increased expression of CB1 receptor. This up-regulation explains the increased potency 
of exogenous cannabinoid agonists during inflammation (110). CB2 receptor agonist 
reduced lipopolysaccharide (LPS) stimulated gastrointestinal transit back to control 
values, and this inhibition was completely prevented by the CB2 receptor antagonist, 
which itself was without effect. The effects of the CB2 agonist were found to act via 
cyclooxygenase in that inhibition of cyclooxygenase with indomethacin completely 
abrogated the inhibitory effect of CB2 agonist. In addition, IL-1βand constitutive NOS 
isoforms (probably eNOS) may be involved in this effect (111). 
In summary, cannabinoids may participate in mucosa damage but delay motility in 
intestinal inflammation via both CB1 and CB2 receptors. 
 
Role in colitis (Figure 5) 
The evidence supported that cannabinoids mediate a protective role in experimental 
colitis via both CB1 and CB2 receptors. For example, studies have shown that 
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intraperitoneal application of the CB1R-selective agonist ACEA and the CB2R-selective 
agonist JWH-133 inhibited Oil of mustard (OM)- and dextran sulfate sodium (DSS)-
induced colitis (112). Inhibitors of anandamide reuptake (VDM11) significantly elevated 
anandamide levels in the colon of DNBS-treated mice and concomitantly abolished 
inflammation (113). In addition, both intrarectal infusion of 2,4-dinitrobenzene sulfonic 
acid (DNBS) and oral administration of dextrane sulfate sodium (DSS) induced stronger 
inflammation in CB1-deficient mice (CB1–/–) than in wild-type littermates (CB1+/+), 
and treatment of wild-type mice with the CB1 antagonist mimicked the phenotype of 
CB1–/– mice, indicating a protective role of the CB1 receptors during inflammation. 
Consistently, treatment with the cannabinoid receptor agonist HU210 or genetic ablation 
of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) resulted in 
protection against DNBS-induced colitis (114). In addition, cannabinoids enhanced 
epithelial wound closure in human colonic epithelial cell lines by the CB1 receptor (88). 
During colitis, the endocannabinoid system was also upregulated. Studies showed that the 
upregulation of CB1 in endothelium and myenteric ganglia, and also CB2R-positive cells 
were evident as a dense, intensely stained infiltrate in OM and DSS colitis tissue (85). 
DNBS treatment also increased the percentage of myenteric neurons expressing CB1 
receptors (114). CB2 immunoreactivity was seen in the epithelium of colonic tissue 
characteristic of inflammatory bowel disease (88). A strong elevation of anandamide, but 
not 2-AG, levels was found in the colon of DNBS-treated mice, in the colon submucosa 
of TNBS-treated rats, and in the biopsies of patients with ulcerative colitis, suggesting the 
protective role of anandamide in colitis and IBDs (113). 
In addition, activation of CB1 and CB2 receptors could play an analgesic role in colon 
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Figure 5. Roles of Cannabinoids and cannabinoid receptors in colitis. 
Continuous arrows denote stimulation and induction. Broken arrows denote inhibition. 
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Figure 5. Roles of Cannabinoids and cannabinoid receptors in colitis. 
Continuous arrows denote stimulation and induction. Broken arrows denote inhibition. 
 
 
 
 
 
 
 
 
31 
inflammation. Studies found that activation of either CB1 or CB2 receptors reduces the 
basal sensitivity and the TNBS colitis-induced hypersensitivity to colorectal distension 
(CRD) in rats, both agonists being more active in the presence of colitis. These effects 
were blocked by their antagonists respectively. CB1 receptor antagonist enhanced colitis-
induced hyperalgesia, suggesting the endogenous cannabinoid system is involved in the 
inflammatory hyperalgesia through CB1 receptors (115). In a model of chronic colonic 
hypersensitivity, elicited by butyrate enemas and mimicking irritable bowel syndrome, 
treatment with probiotic bacteria NCFM significantly increased the colorectal distension 
threshold which was inhibited by CB2-selective antagonist; in addition, administration of 
NCFM significantly induced the expression of CB2 in epithelial cells of colonic section 
of rats and mice, providing indirect evidence for a physiological role of CB2 in the 
control of intestinal pain (116). 
In summary, cannabinoids play a protective role in inflammatory damage and analgesic 
role in colitis via both CB1 and CB2 receptors.  
 
Cannabinoids in central nervous system 
The role of cannabinoids in the brain has been well studied. Cannabinoids suppressed 
neuronal activity via CB1 presynaptic inhibition of neurotransmitters release in 
hippocampal and cerebellar neurons (117-123). In addition, endocannabinoids were 
involved in regulation of food intake (124), inhibition of emesis (125) and analgesia 
(126,127). 
The effect of cannabinoids on neuronal survival has been studied by many groups, 
however, the results are controversial varying from neuroprotection (128-132) to 
neurotoxity (133-135). For example, cannabinoids mediate a neuroprotective effects in 
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neurotoxin S-AMPA induced primary cortical neurons death (131). Moreover, the 
endocannabinoid system is highly activated during CNS inflammation and anandamide 
protects neurons from inflammatory damage via CB1/2 receptors (130). In contrast, 
anandamide was also found to induce cell death in primary neuronal cultures via calpain 
and caspase pathways (134). Δ9-THC induced apoptosis in cultured rat cortical neurons 
via P53 (135).  
 
Hypothesis 
Although the major effects of cannabinoids in the gut are mediated through effects on 
enteric neurons, the role of cannabinoids in enteric nervous system is poorly understood. 
Given the importance of cannabinoids in inflammation of gut and their effects in neuronal 
survival and death in CNS, we hypothesize that cannabinoids could affect enteric 
neuronal survival and we will identify the pathways involved. Since the endocannabinoid 
system is upregulated in inflammatory bowel diseases, this effect may play a role in the 
pathogenesis of the response to inflammation as well as the recovery and reinnervation of 
the gut following the acute phase of inflammation. The further significance of this work 
could contribute to developing new therapeutic methods for inflammatory bowel disease 
and related symptoms in clinic practice.  
 
 
 
 
 
 Materials and Methods 
 
Materials 
Materials for cell culture 
Hartley guinea pigs (150-200g, male) were purchased from Charles River Laboratories 
(Wilmington, MA). All procedures with animals were approved by the Institutional 
Animal Care and Use Committee at Virginia Commonwealth University.  
Dulbecco Modified Eagle’s Medium (DMEM) was purchased from Invitrogen 
(Frederick, MD). 10% fetal bovine serum (FBS) was purchased from Atlas (Tartu, 
Estonia). The fetal enteric neuronal cell line was a kind gift from Dr. Srinivasan’s group 
(University of Emory). DMEM-F12, N2 medium, Neurobasal A medium, B-27 serum-
free supplement, 0.25% Trypsin-EDTA were purchased from Invitrogen  (Frederick, 
MA). rhGDNF was purchased from Promega (Madison, WI). C8-D1A (Astrocyte type I 
clone) was purchased from ATCC (Manassas, VA). 
 
Antibodies  
Monoclonal to PGP9.5 (Mouse) was purchased from Abcam Inc. (Cambridge, MA). CB1 
(N-15) (Goat) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
Anti-protein gene product 9.5 (PGP9.5) (Rabbit), anti-S-100 protein monoclonal antibody 
(Mouse) and anti-cannabinoid receptor 2, N-terminus (Rabbit) were purchased from 
Millipore (Billerica, MA). Alexa Fluor 488 (donkey anti-mouse) and Alexa Fluor 594 
(donkey anti-goat, donkey anti-guinea pig and donkey anti-rabbit) are purchased from 
Invitrogen (Frederick, MA).  
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (rabbit) and p44/42 MAPK 
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(Erk1/2) antibody (rabbit) were purchased from Cell signaling (Danvers, MA). 
Monoclonal anti-β-actin (mouse, 1:10000) was purchased from Sigma (St. Louis, MO). 
Anti-CB1 antibody (rabbit) was purchased from Affinity Bioreagents (Golden, CO). HRP 
conjugated 2nd antibodies: goat anti-rabbit (1:1000) and goat anti-mouse (1:1000) and 
Supersignal west femto chemiluminescent substrate were purchased from Pierce 
(Rockford, IL). Odyssey 2nd antibodies: rabbit (1:10000) and mouse (1:10000) were 
purchased from Licor Biosciences (Lincoln, NE).  
 
Other chemicals 
Vectastain elite ABC kit (rabbit IgG) and Peroxidase substrate 3, 3’ Diaminobenzidine 
(DAB) kit were purchased from Vector Laboratories, Inc. (Burlingame, CA). Protease 
inhibitor cocktail was purchased from BD Biosciences (Palo Alto, CA). Protein assay kit 
was purchased from Biorad (Hercules, CA). AM251, AM630, Capsazepine, MAP kinase 
kinase (MEK) inhibitor PD98059, Phospholipase C (PLC) inhibitor U73122, 
Phosphatidylinositol-3-kinase (PI-3K) inhibitor LY 294002 and other chemicals were 
purchased from Sigma (St. Louis, MO).  
 
Methods 
Collection of tissue 
Guinea pigs were sacrificed by CO2 asphyxiation. The small intestine was dissected out 
immediately and placed in 37ºC oxygenated Krebs solution of the following composition: 
NaCl 118 mM, KCl 4.75 mM, KH2PO4 1.19 mM, MgSO4 1.2 mM, CaCl2 2.54 mM, 
NaHCO3 25 mM and Dextrose 11 mM (pH 7.4).  
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Preparations of ganglia from guinea pig myenteric plexus 
The tissue was cut into 3-4 cm sections for preparation of myenteric ganglia by the 
method of Yau (138). The segments of intestine were placed on glass rods and the sheets 
of longitudinal muscle with the myenteric plexus were scrapped with a wet Kim wipe and 
incubated for 6 minutes at 37ºC in Krebs-bicarbonate solution containing 0.1% protease, 
0.2% collagenase type IV and 0.1% BSA for enzymatic digestion. The tissue was 
consistently bubbled with 95%O2/5%CO2, accompanied by frequently suctioning with 5 
ml pipette to free the ganglia from the smooth muscle cells during this process. The partly 
digested tissue was then collected by filtering through 500-um Nitex mesh and incubated 
for one hour at 37ºC in enzyme-free Krebs solution bubbling with 95%O2/5%CO2 for 
further isolation. The suspension was then filtered to remove the undigested tissue and 
the filtrate was centrifuged for 1 minute at 1000 RPM. The supernatant containing 
smooth muscle cells and debris was discarded, and the pellet containing the ganglia was 
resuspended and washed twice in enzyme-free Krebs solution to remove cell debris. Then 
the pellet was resuspended and placed in a 10cm plastic culture dish and the ganglia were 
harvested by suction into 20ul capillary tube under dissecting microscope.   
 
Cultures in plates for treatment with anandamide and other reagents 
Ganglia were placed in 24 well plates with a density of 15 ganglia per well, and incubated 
for three days in Dulbecco Modified Eagle’s Medium (DMEM) containing 200U/ml 
penicillin, 200ug/ml streptomycin, 100ug/ml gentamycin, 2.5 ug/ml amphotericin B and 
10% fetal bovine serum (DMEM10) at 37ºC 10%CO2 incubator. In some experiments, 
the ganglia were incubated in DMEM10 containing 10uM of mitotic inhibitor arabinoside 
cytosine (araC) to reduce the glial and other nonneural cell effects on the neurons. After 
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three days incubation, the ganglia attached to the bottom of the plates. The wells were 
washed two times with serum free medium (DMEM0) containing 200U/ml penicillin, 
200ug/ml streptomycin, 2.5ug/ml amphotericin B, and 100ug/ml gentamycin and treated 
with anandamide (1nM-10uM) and/or the CB1 antagonist AM251 (1uM) or CB2 
antagonist AM630 (1uM) or TRPV1 antagonist capsazepine (1uM) in serum free medium 
DMEM0 or DMEM0 with 10uM araC for four days. In one set of experiments, the 
ganglia were treated with 0.1uM anandamide and/or MAP kinase kinase (MEK) inhibitor 
PD98059 (1uM) or phospholipase C (PLC) inhibitor U73122 (1uM) or 
phosphatidylinositol-3-kinase (PI-3K) inhibitor LY 294002 (1uM). Untreated wells were 
taken as a control. Duplicates were done for each treatment in each animal. The plates 
were then prepared for immunohistochemistry. 
 
Immunohistochemistry 
The plates were washed three times with phosphate buffer saline (PBS) solution 
containing 137mM NaCl, 2.682 mM KCl, 3.895 mM Na2HPO4 and 1.764mM KH2PO4 at 
4 ºC, and fixed with 4% paraformaldehyde with the following composition: 0.04g/ml 
paraformaldehyde, 2.5mM NaOH, 28mM NaH2PO4 and 37.4mM Na2HPO4 for 30 
minutes. The cells were then washed twice with PBS, and incubated with 0.1% triton X-
100 for 10 minutes. After blocking with normal goat serum (NGS) from VECTASTAIN 
ABC kit (Vector Laboratories) for 20 minutes, the plates were incubated with primary 
antibody to protein gene product 9.5 (anti-PGP9.5) (rabbit, Millipore Corp.) diluted 
1:1000 in PBS containing 1% blocking serum at 4 ºC for 24 hours.   
On the second day, the cultures were washed three times with PBS and incubated with the 
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biotinylated secondary antibody (goat anti-rabbit) for 30 minutes. After washing with 
PBS for 5 minutes, wells were incubated with the conjugate of Avidin/Biotinylated 
horseradish peroxidase (HRP) complex (VECTASTAIN ABC kit, Vector Laboratories) 
for 30 minutes. Then washing once with PBS for 5 minutes, the ganglia were incubated 
with 3, 3’-Diaminodenzidine (DAB) working solution from DAB kit (Vector Laboratories, 
Inc.) for 4-10 minutes. After washing with distilled water for 5 minutes, the wells were 
coved with Crystal/Mount (Biomeda Corp.) and placed at 70 ºC for 10 minutes to dry. 
These plates were examined under an inverted light microscope. 
 
Counting of neurons and ganglia and calculations 
After staining with the neuronal marker anti-PGP9.5 antibody, the number of ganglia in 
each well and the number of neurons in each ganglion were counted. The total number of 
neurons was calculated by adding the number of neurons in each ganglion together in 
each well. The percentage changes were calculated through the control divided by the 
treated groups. The survivals were expressed as the mean of percentage change from 
control ±standard error of the mean (SEM).  
 
Cultures for immunofluoresence staining  
In this protocol, ganglia were placed in 8 well slides with a density of 15 ganglia per well, 
and incubated in DMEM10 medium for seven days at 37ºC 10%CO2 incubator. The 
medium was replaced on day 3. Then the ganglia were prepared for immunofluoresence 
staining. 
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Immunofluoresence staining  
After culture of ganglia on 8 well slides for seven days, the slides were washed three 
times with IHC solution containing 26mM NaH2PO4 and 39mM Na2HPO4 and fixed with 
4% paraformaldehyde as described above for 30 minutes. After washing two times with 
IHC solution, the ganglia were treated with 0.3% Triton X-100 for 10 minutes to 
permeabilized the cells and incubated for 20 minutes with 3% donkey normal serum 
(DNS) to block the nonspecific binding of the antibody. The cultures were then incubated 
with the primary antibodies to PGP9.5 (mouse, Abcam) (1:500), S-100 (mouse, 
Chemicon) (1:100), CB1 (goat, Santa cruz) (1:100), and CB2 (rabbit, Millipore) (1:100) 
at 4 ºC for 24 hours. All primary antibodies were diluted with 3% DNS to inhibit the 
nonspecific binding. Negative controls were performed by deleting the primary 
antibodies. 
On the second day, the slides were washed three times with IHC and incubated two hours 
in dark place at room temperature with the secondary antibodies conjugated to either 
Alexa Fluor 488 (1:500) or Alexa Fluo 594 (1:500). The secondary antibodies were 
determined according to the species of the primary. After incubation, the slides were 
washed three times with IHC solution, covered with permaflour, covered with a glass 
coverslip, and placed in the dark place for 24 hours to dry. Then slides were sealed with 
nail polish and examined under the microscope with appropriate filters for Alexa Fluor 
488 or Alexa Fluor 594.  
 
Cultures for enteric neuronal cell line 
The enteric neuronal cell line was cultured by the method of Anitha et al (139). The 
 
39 
frozen cells were thawed at 37ºC for 2-3 minutes, suspended in 10ml N2 medium with 
the following composition: DMEM-F12 medium, N2 medium, 10ng/ml GDNF, 10% FBS, 
200U/ml penicillin and 200ug/ml streptomycin and centrifuged for 5 min at 130 x g to 
remove DMSO. The cells were then resuspended in N2 medium and placed onto T-25 
flasks. The flasks were cultured in a humidified incubator containing 10%CO2 at 
permissive temperature 33 ºC for proliferation until confluence was attained. The cells in 
flask were then dislodged mechanically by trypsin-ethylenediaminetetraacetic acid 
(0.25%) and re-plated on 8 well slides and/or 6 well plates at a concentration of 5 X 105 
cells/ml in N2 medium. The cells were then incubated for the following protocols. All 
experiments were performed between passages 13 and 40 and duplicates were done for 
each treatment in each experiment. 
Non-treated wells for immunofluoresence staining 
The 8 well slides were cultured at 33 ºC for 2-3 days, and then move to 5% CO2 39 ºC 
incubator in neurobasal-A medium containing B-27 serum-free supplement, 1mmol/L 
glutamine, 5uM Na3VO4, 200U/ml penicillin and 200ug/ml streptomycin for 7 days. The 
medium was replaced once on day 3. Then the slides were prepared for 
immunofluoresence staining with anti-PGP9.5 (rabbit, 1:1000), anti-CB1 (goat, 1:50) or 
anti-CB2 (rabbit, 1:200) antibodies as described above. 
Treatment with anandamide at 39 degree for 7 days. 
The 8 well slides and 6 well plates were cultured at 33 ºC for 2-3 days, and then treated 
with anandamide (0, 1nM, 0.1uM, 10uM) diluted in neurobasal-A medium for 7 days at 
5% CO2 39 ºC incubator. The medium was replaced once on day 3. The slides were then 
immunostained with anti-PGP9.5 antibody (rabbit, Millipore) as described above. The 
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cells grown in plates were prepared for western blot. 
Treatment with anandamide at 33 degree for 2 days. 
To eliminate the effect of anandamide on cell differentiation at 39 degree, the slides were 
cultured at 33 ºC in N2 medium for 24 hours. After this incubation the cells were settled 
to the bottom of the slides. The slides were then treated with anandamide (0, 1nM, 0.1uM, 
10uM) diluted in N2 medium and continued to incubate at 33 ºC for 2 days.  The medium 
of slides was changed to neurobasal-A medium without anandamide and cultured for 7 
days at 5% CO2 39 ºC incubator. The slides were then immunostained with anti-PGP9.5 
antibody (rabbit, Millipore) as described above and examined under microscope. 
 
Coculture of astrocyte cell line with enteric neuronal cell line and treatment with 
anandamide. 
The astrocyte cell line was thawed in 37ºC for 2-3 minutes, transferred to 75cm2 tissue 
culture flasks and diluted in DMEM containing 200U/ml penicillin, 200ug/ml 
streptomycin, 100ug/ml gentamycin, 2.5ug/ml amphotericin B and 10% fetal bovine 
serum (DMEM10). The flasks were then placed at 5% CO2 37 ºC incubator until 
confluence. The cells were dispersed by 0.25% (w/v) trypsin-0.53Mm EDTA solution and 
re-plated on 8 well slides at a concentration of 1 X 105 cells/ml in DMEM10 medium for 
24 hours at 5% CO2 37 ºC incubator. After this incubation, the cells adhered to the 
bottom of the slides. 
Then the medium was removed and the enteric neuronal cell line was plated on these 
slides at a concentration of 5 X 105 cells/ml in N2 medium for 2-3 days at 33ºC incubator. 
The slides cocultured astrocyte cell line and enteric neuronal cell line were then treated 
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with anandamide (0, 1nM, 0.1uM, 10uM) diluted in neurobasal-A medium for 7 days at 
5% CO2 39 ºC incubator. The medium was replaced once on day 3. The slides were 
immunostained with anti-PGP9.5 antibody on day 7 (rabbit, Millipore) as described 
above. Duplicate wells were done for each treatment in each experiment. 
 
Counting of neuronal cells and calculations 
The PGP9.5 immunoreactive cells were identified as the neuronal cells. The number of 
neuronal cells and the number of total cells were counted in a 0.1215mm2 grid and three 
randomly selected fields per well were examined. The neuronal cell percent was 
calculated using the number of neuronal cells divided by the number of total cells per grid. 
The percentage changes were calculated through the control divided by the treated groups. 
Neuronal survival is expressed as the mean of percentage change of PGP9.5-positive cells 
in total cells ±SEM.  
In coculture slides, the astrocytes and enteric neuronal cells are easily differentiated and 
neuronal survival is expressed as the mean of percentage change of PGP9.5-positive cells 
in total enteric neuronal cells ±SEM. 
 
Protein concentration assay and western blot analysis  
Protein extraction 
After treatment with anandamide, the enteric neuronal cells grown in 6 well plates were 
prepared for protein exaction. The plates were rinsed with cold PBS twice and then 
incubated in 0.3ml/well lysis buffer solution containing 50mM Tris/Cl, pH 7.5, 150mM 
NaCl, 0.1%SDS, 0.5% Sodium deoxycholate, 1% NP-40, 10mM Sodium pyrophosphate 
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and protease inhibitor cocktail (BD Biosciences) containing 16 ug/ml benzamidine HCl, 
10 ug/ml phenanthroline, 10ug/ml aprotinin, 10ug/ml leupeptin, 10ug/ml pepstatin A, and 
1mM PMSF for 1-2 minutes. The cells were scrapped off and sonicated for 10 seconds to 
disrupt the cells. The samples were centrifuged for 20 minutes at 4 ºC. The supernatant 
was then transferred to new vials for Biorad protein assay and western blot and the pellet 
was discarded. 
Biorad protein assay 
The BSA standards (2.0, 1.2, 1.0 0.8, 0.6, 0.4, 0.2 and 0 mg/ml) were used for generating 
a standard curve. The protein concentration of samples was determined from the X-axis 
of the standard curve.  
Western blot 
The protein extracts were resolved using 10% SDS/PAGE gel and then transferred onto a 
nitrocellulose membrane for two hours at 4ºC in 100-125 volts. After blocking with 5% 
milk for one hour, the membranes were incubated with primary antibodies for 24 hours at 
4ºC. The membranes were then washed three times with Tris Buffered Saline Tween-20 
(TBST) buffer and incubated with Odyssey fluorescent secondary antibodies for one 
hour. After three times washes with TBST, the membranes were developed by Odyssey. 
The band intensities were quantitated by Odyssey software. For detecting the CB2 
expression in enteric neuronal cell line, the horseradish peroxidase-conjugated secondary 
antibody (1:1000) was used and the protein bands were identified by Supersignal west 
femto chemiluminescent kit (Thermo scientific).  
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Statistics 
The results are expressed as means + SEM. of n experiments and analyzed for statistical 
significance using Student’s t-test or ANOVA. The probability of P<0.05 was considered 
statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Results 
 
Ganglion isolation and growth 
The myenteric ganglia were successfully isolated from the guinea pig small intestine, and 
visualized in phase contrast microscopy (Figure 6, left panel). Then each well of the 
culture plates was seeded with 15 ganglia and grown in DMEM 10 medium for 3 days; at 
this stage the ganglia were attached to the floor of culture slides, and glia and neurons 
began expanding their processes and neurites. Then the ganglia were grown in DMEM0 
medium for 4 days and immunostained with an antibody to the general neuronal marker 
PGP9.5. The enteric neurons can be easily identified after this process as shown in Figure 
6 (right panel).  
 
Effect of anandamide on ganglionic survival 
After 7 days in culture, the average number of ganglia per well was 6.05±0.67 in the 
control group (Figure not shown). The results with anandamide treatment indicated that 
anandamide had a biphasic effect on ganglionic survival, increasing survival at low 
concentrations (1nM-0.1uM) and decreasing survival at high concentration (10uM). 
Maximal survival (68% increase in number of ganglia surviving) occurred at 0.1uM and 
the ED50 was 3nM (Figure 7).  
To differentiate which cannabinoid receptor(s) mediated these effects, primary cultures 
were treated with anandamide and CB1 cannabinoid receptor antagonist, AM251 (1uM).  
44 
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Figure 6. Images of freshly isolated ganglia (left) and ganglia grown 7 days in culture 
(right).  
Left panel illustrates freshly isolated ganglia from guinea pig intestine and right panel 
shows a ganglia grown 3 days in DMEM10 and another 4 days in DMEM0 culture 
medium and immunostained with neuronal marker anti-PGP9.5 antibody. 
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Figure 7. Anandamide dose response curve for ganglia survival in absence of araC.  
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with 
anandamide (1nM-10uM) in DMEM0 medium for 4 days. The number of ganglia was 
counted on day 7 after immunostained with neuronal marker anti-PGP9.5 antibody. 
Anandamide had a biphasic effect on ganglionic survival, increasing survival at low 
concentrations (1nM-0.1uM) and decreasing survival at high concentration (10uM). 
Maximal survival (68% increase in number of ganglia surviving) occurred at 0.1uM and 
the ED50 was 3nM. Ganglionic survival is expressed as percentage change from control. 
Values are means±SEM of 9 animals. * = P<0.05. 
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As shown in Figure 8, anandamide induced increase in survival was inhibited by AM251, 
suggesting this effect was mediated by CB1 receptors. The CB1 antagonist alone had no 
effect on the number of ganglia surviving compared with control, suggesting endogenous 
cannabinoids may not play a role in ganglia survival through CB1 receptor. In addition, 
AM251 did not block the decreased survival of ganlia induced by the higher 
concentration of anandamide (10uM) . This suggested that the decrease in survial of 
ganglia was not due to CB1 receptors. 
Next we examined whether CB2 receptors play a role in the ganglia survival. We used 
the CB2 receptor specific antagonist AM630 to address this question. Again, anandamide 
had a biphasic effect on ganglionic survival, increasing survival at low concentration 
(0.1uM) and decreasing survival at high concentration (10uM). The effect of anandamide 
on promoting survival was not inhibited by CB2 antagonist AM630 (1uM); however, the 
effect on decreasing survival was significantly inhibited by AM630 (Figure 9). These 
results suggested that high concentration of anandamide activate CB2 receptors and 
decrease ganglia survival. The results also suggest that CB2 receptor was not involved in 
the increase in ganglia survial induced by low concentrations of anandamide (0.1uM). 
The CB2 antagonist alone had no effect on the cultured ganglia survival, suggesting 
endogenous cannabinoid may not play a role in ganglia survival through CB2 receptor 
(Figure 9). 
The TRPV1 receptor can be found in extrinsic primary sensory neurons as well as 
intrinsic sensory neurons. There are some evidence that anandamide could activate the 
TRPV1 receptor, although at high concentrations. Here we tested whether the effect of 
anandamide on ganglionic survival involved TRPV1. We found that both the  
 
50 
 
 
 
 
 
Figure 8. Anandamide dose response curve for ganglia survival with CB1 antagonist in 
absence of araC.  
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with 
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated 
additionally with the CB1 receptor antagonist, AM251 (1uM) on day 3. The number of 
ganglia was counted on day 7 after immunostained with neuronal marker anti-PGP9.5 
antibody. Anandamide had a biphasic effect on ganglionic survival, increasing survival at 
low concentration (0.1uM) and decreasing survival at high concentration (10uM). The 
effect of anandamide on increasing ganglia survival was inhibited by AM251. Ganglionic 
survival is expressed as percentage change from control. Values are means±SEM of 9 
animals. * = P<0.05. 
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Figure 9. Anandamide dose response curve for ganglia survival with CB2 antagonist 
AM630 in absence of araC.  
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with 
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated 
additionally with the CB2 receptor antagonist, AM630 (1uM) on day 3. The number of 
ganglia was counted on day 7 after immunostained with neuronal marker anti-PGP9.5 
antibody. Anandamide had a biphasic effect on ganglionic survival, increasing survival at 
low concentration (0.1uM) and decreasing survival at high concentration (10uM). The 
effect of anandamide on decreasing survival was significantly inhibited by AM630 
(1uM). Ganglionic survival is expressed as percentage change from control. Values are 
means±SEM of 15 animals for control and 6 animals for AM630. * = P<0.05. 
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promoting and decreasing effects of anadamide on ganglia survival were not inhibited by 
TRPV1 antagonist capsazepine (1uM). The TRPV1 antagonist alone also had no effect on 
the cultured ganglia survival. These data suggest that the TRPV1 receptor may not play a 
role in anandamide-mediated ganglia survival (Figure 10).Taken together, these data 
suggest that anandamide promotes ganglia survival at low concentration (0.1uM) by 
interaction with CB1 receptors and decreases ganglia survival at high concentration by 
interaction with CB2 receptors. 
 
Enteric glia involved in anandamide mediated ganglionic survival 
The enteric ganglia included enteric neurons and enteric glia. Next, we examined the 
effect of anandamide on the ganglion survival in absence of enteric glia cells. We used 
cytosine arabinoside (araC) to inhibit rapidly dividing cells and to reduce most of the 
enteric glia cells. After 7 days in culture with araC treatment, the average number of 
ganglia was 4.83±1.97 in the control group (Figure not shown). The results with 
anandamide treatment under these conditions are shown in Figure 11. Anandamide, at 
low concentrations (1nM-0.1uM), had no effect on ganglionic survival in presence of 
araC. So in the absence of enteric glia cells, anandamide lost its ability to promote 
ganglia survival, suggesting this effect involved the glia cells. At higher concentration 
10uM, anandamide inhibited the ganglia survival by 63% just as it did in the absence of 
araC. AM251 did not reverse this inhibition, suggesting that the inhibition by anandamide 
was not mediated by CB1 receptor. AM251 alone had no effect on the cultured ganglia 
survival (Figure 12). 
Next we want to know whether CB2 receptor still play a role in ganglia death in the  
 
55 
 
 
 
 
 
Figure 10. Anandamide dose response curve for ganglia survival with TRPV1 antagonist 
capsazepine in absence of araC.  
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with 
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated 
additionally with the TRPV1 receptor antagonist, capsazepine (1uM) on day 3. The 
number of ganglia was counted on day 7 after immunostained with neuronal marker anti-
PGP9.5 antibody. Both promoting and decreasing survival were not inhibited by TRPV1 
antagonist capsazepine. The TRPV antagonist alone also had no effect on the cultured 
ganglia survival. Ganglionic survival is expressed as percentage change from control. 
Values are means±SEM of 15 animals for control and 3 animals for capsazepine group. * 
= P<0.05. 
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Figure 11. Anandamide dose response curve for ganglia survival in presence of araC  
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC; 
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium 
with araC for 4 days. The number of ganglia was counted on day 7 after immunostained 
with neuronal marker anti-PGP9.5 antibody. Anandamide, at low concentrations (1nM-
0.1uM), had no effect on ganglionic survival in presence of araC. At high concentration 
(10uM), anandamide inhibited the ganglia survival by 63%. Ganglionic survival is 
expressed as percentage change from control. Values are means±SEM of 7 animals. * = 
P<0.05. 
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Figure 12. Anandamide dose response curve for ganglia survival with CB1 antagonist in 
presence of araC  
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC; 
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium 
with araC for 4 days. Some cultures were treated additionally with the CB1 receptor 
antagonist, AM251 (1uM) on day 3. The number of ganglia was counted on day 7 after 
immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide (10uM) 
inhibited the ganglia survival by 63%, which was not reversed by AM251. Ganglionic 
survival is expressed as percentage change from control. Values are means±SEM of 7 
animals. * = P<0.05. 
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absence of glia cells. As shown in Figure 13, again after reducing glia cells, anandamide, 
at low concentrations (1nM-0.1uM), had no effect on ganglionic survival and inhibited 
the ganglia survival at higher concentration (10uM). AM630 (1uM) reduced the level of 
inhibition of growth by high concentrations of andamide (10 uM) but this did not achieve 
significance, suggesting that CB2 receptors in both neurons and glia cells could 
participate in high concentration anandamide induced ganglia death. The CB2 antagonist 
alone had no effect on the cultured ganglia survival.  
Taken together, these data suggested that enteric glia cells were involved in anandamide 
mediated ganglion survival. Anandamide may act on CB1 receptors in enteric glia to 
promote ganglia survival and on CB2 receptors in both enteric neurons and glia to inhibit 
survival. 
 
Effect of anandamide on neuronal survival 
Next we want to know whether anandamide affected the enteric neuronal survival. We 
examined the number of neurons in each ganglia and the total number of neurons in each 
well. After 7 days in cultures, the number of neurons in each ganglion is 19.11±1.44 
(Figure 14) and the number of total neurons in each well is 116.71±14.76 (Figure 15) in 
control group. Anandamide (1nM-10uM) did not change the number of neurons/ganglion 
significantly in presence of enteric glia (Figure 16), however, similar to the effect on 
ganglia survival, anandamide tended to increase the survival of total neurons per well at 
low concentrations (1nM-0.1uM) and decrease it at higher concentrations (1uM-10uM) in 
the presence of enteric glia. Maximal survival (66% increase in number of total neurons) 
occurred at 0.1uM (Figure 17). This data suggest anandamide could increase neuronal  
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Figure 13. Anandamide dose response curve for ganglia survival with CB2 antagonist 
AM630 in presence of araC. 
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC; 
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium 
with araC for 4 days. Some cultures were treated additionally with the CB2 receptor 
antagonist, AM630 (1uM) on day 3. The number of ganglia was counted on day 7 after 
immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide inhibited the 
ganglia survival at higher concentration (10uM) and AM630 was not able to block this 
inhibition significantly in the presence of araC. Ganglionic survival is expressed as 
percentage change from control. Values are means±SEM of 4 animals. * = P<0.05. 
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Figure 14. Effect of CB1 antagonist on neurons in ganglia in absence of araC. 
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with 
the CB1 receptor antagonist, AM251 (1uM) in DMEM0 medium for 4 days. The number 
of neurons in ganglia was counted on day 7 after immunostained with neuronal marker 
anti-PGP9.5 antibody. CB1 antagonist AM251 (1uM) alone had no effect on the number 
of neurons/ganglion in the absence of araC. Neuronal survival is expressed as the number 
of neurons per ganglia. Values are means±SEM of 9 animals. 
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Figure 15. Effect of CB1 antagonist on total neurons per well in absence of araC. 
ch well Primary cultures of enteric ganglia were prepared from guinea pig intestine. Ea
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with 
the CB1 receptor antagonist, AM251 (1uM) in DMEM0 medium for 4 days. The number 
of total neurons per well was counted on day 7 after immunostained with neuronal 
marker anti-PGP9.5 antibody. CB1 antagonist AM251 (1uM) alone had no effect on the 
number of total neurons per well in the absence of araC. Neuronal survival is expressed 
as the number of neurons per ganglia. Values are means±SEM of 9 animals. 
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Figure 16. Neurons in ganglia dose response to anandamide in absence of araC. 
ach well Primary cultures of enteric ganglia were prepared from guinea pig intestine. E
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with 
anandamide (1nM-10uM) in DMEM0 medium for 4 days. The number of neurons in 
ganglia was counted on day 7 after immunostained with neuronal marker anti-PGP9.5 
antibody. In the absence of araC, anandamide (1nM-10uM) did not change the number of 
neurons/ganglion significantly. Neuronal survival is expressed as percentage change from 
control. Values are means±SEM of 9 animals. 
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Figure 17. The number of total neurons per well dose response to anandamide in absence 
ultures of enteric ganglia were prepared from guinea pig intestine. Each well 
of araC. 
Primary c
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with 
anandamide (1nM-10uM) in DMEM0 medium for 4 days. The number of total neurons 
per well was counted on day 7 after immunostained with neuronal marker anti-PGP9.5 
antibody. Anandamide tended to increase the survival of total neurons per well at low 
concentrations (1nM-0.1uM) and decrease it at higher concentrations (1uM-10uM) in the 
absence of araC. Maximal survival (66% increase in number of total neurons) occurred at 
0.1uM. Neuronal survival is expressed as percentage change from control. Values are 
means±SEM of 9 animals. 
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survival through promoting the ganglionic survival, which is mediated by CB1 receptors.  
0.1uM) and AM630 together, significantly increased the 
nhibition of neuronal survival by anandamide in absence of enteric glia 
data suggested that anandamide inhibited neuronal survival when enteric glia cells were  
AM251 (1uM) alone had no effect on the number of neurons/ganglion (Figure 14) and 
the number of total neurons/well (Figure 15), suggesting endogenous cannabinoids may 
not be involved in neuronal survival through the CB1 receptor. Treatment with 
anandamide and AM251 together did not change the number of neurons/ganglion either 
(Figure 18). However, AM251 (1uM) tended to inhibit the effect of anandamide on total 
neuronal survival (Figure 19). This effect may also have been the result of the effect of 
AM251 on ganglion survival. 
Treatment with anandamide (
neuronal survival in ganglia by 35%. AM630 alone also tended to increase neuronal 
survival in ganglia (Figure 20). In addition, AM630 increased total neuronal survival per 
well significantly when added alone or in combination with anandamide (10uM) (Figure 
21). These data suggested that blockade of CB2 receptor may increase neuronal survival 
in the presence of glia and suggests that activation of CB2 receptors inhibits neuronal 
suvival in the presence of glia. 
 
I
As described earlier, we reduced the enteric glia cells by araC to distinguish the direct 
role of anandamide on neuronal survival. Low concentrations of anandamide (1nM-
0.1uM) decreased the number of neurons/ganglion by 15-20% in the presence of araC 
(Figure 22). At higher concentrations, anandamide also (1nM-10uM) decreased the 
number of total neurons per well by 13-66% in the presence of araC (Figure 23).  These 
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Figure 18. Neurons in ganglia dose response to anandamide with CB1 antagonist in 
bsence of araC. 
5 ganglia grown in DMEM10 medium for 3 days and then treated with 
a
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 1
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated 
additionally with the CB1 receptor antagonist, AM251 (1uM) on day 3. The number of 
neurons in ganglia was counted on day 7 after immunostained with neuronal marker anti-
PGP9.5 antibody. In the absence of araC, anandamide (1nM-10uM) alone or treated with 
AM251 together did not change the number of neurons/ganglion significantly. Neuronal 
survival is expressed as percentage change from control. Values are means±SEM of 9 
animals. 
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Figure 19. The Number of total neurons per well dose response to anandamide with CB1 
ntagonist in absence of araC. 
wn in DMEM10 medium for 3 days and then treated with 
a
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 ganglia gro
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated 
additionally with the CB1 receptor antagonist, AM251 (1uM) on day 3. The number of 
total neurons per well was counted on day 7 after immunostained with neuronal marker 
anti-PGP9.5 antibody. Anandamide tended to increase the survival of total neurons per 
well at low concentrations (1nM-0.1uM) and decrease it at higher concentrations (1uM-
10uM) in the absence of araC. Maximal survival (66% increase in number of total 
neurons) occurred at 0.1uM. AM251 (1uM) tended to inhibit the effect of anandamide at 
low concentrations. Neuronal survival is expressed as percentage change from control. 
Values are means±SEM of 9 animals.  
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Figure 20. Neurons in ganglia dose response to anandamide with CB2 antagonist AM630 
 absence of araC. 
ganglia grown in DMEM10 medium for 3 days and then treated with 
in
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated 
additionally with the CB2 receptor antagonist, AM630 (1uM) on day 3. The number of 
neurons in ganglia was counted on day 7 after immnostained with neuronal marker anti-
PGP9.5 antibody. Treatmentment anandamide (0.1uM) and AM630 together, AM630 
significantly promote the neuronal survival in ganglia by 35%. Neuronal survival is 
expressed as percentage change from control. Values are means±SEM of 15 animals for 
control and 6 animals for AM630. * = P<0.05. 
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Figure 21. The Number of total neurons per well dose response to anandamide with CB2 
ntagonist AM630 in absence of araC. 
MEM10 medium for 3 days and then treated with 
a
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15 ganglia grown in D
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated 
additionally with the CB2 receptor antagonist, AM630 (1uM) on day 3. The number of 
total neurons per well was counted on day 7 after immmnuostained with neuronal marker 
anti-PGP9.5 antibody. AM630 promoted the total neuronal survival per well significantly 
when treated with anandamide (10uM) together. Neuronal survival is expressed as 
percentage change from control. Values are means±SEM of 15 animals for control and 6 
animals for AM630 group. * = P<0.05. 
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Figure 22. Neurons in ganglia dose response to anandamide in presence of araC. 
rimary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
e (araC; 
P
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinosid
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium 
with araC for 4 days. Some cultures were treated additionally with the CB1 receptor 
antagonist AM251 (1uM) on day 3.The number of neurons in ganglia was counted on day 
7 after immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide (1nM-
0.1uM) decreased the number of neurons/ganglion by 15-20% in the presence of araC. 
Data was shown in doses 10nM and 10uM. Neuronal survival is expressed as percentage 
change from control. Values are means±SEM of 7 animals. * = P<0.05. 
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Figure 23. The Number of total neurons per well dose response to anandamide in 
resence of araC. 
 ganglia grown in DMEM10 medium with cytosine arabinoside (araC; 
p
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
was seeded with 15
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium 
with araC for 4 days. Some cultures were treated additionally with the CB1 receptor 
antagonist, AM251 (1uM) on day 3. The number of total neurons per well was counted 
on day 7 after immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide 
(1nM-10uM) decreased the number of total neurons per well by 13-66% in the presence 
of araC. Data was shown in doses 10nM and 10uM. Neuronal survival is expressed as 
percentage change from control. Values are means±SEM of 7 animals. * = P<0.05. 
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not present in the cultures. This is very different from the condition in the presence of glia 
.,e., absence of araC,) where anadamide had a biphasic effect on the number of total 
andamide on the neuronal 
 (1nM-0.1uM) decreased the 
Taken together, anandamide decreased neuronal survival without enteric glia cells, which  
(i
neurons, increasing the number of neurons at low concentrations and decreasing the total 
number of neurons at higher concentrations (see Figure 17).  
The decrease in the number of neurons/ganglion was partially reversed by AM251 (1uM) 
(Figure 24 and 25), which suggested that inhibition of an
survival was partially mediated by CB1 receptors. In addition, AM251 (1uM) tended to 
inhibit the effect of anandamide on the number of total neurons/well at low 
concentrations (1nM-0.1uM) although not significantly, and had no significant effect at 
the highest concentration of anandamide (10uM). Again, AM251 alone had no effect on 
the neuronal survival in the presence of araC (Figure 25). 
Next, we wanted to know whether this inhibition by anandamide also involved CB2 
receptors. The results showed that again, anandamide
number of neurons/ganglion by 17-30% in the presence of araC and this was not 
significantly blocked by AM630 (1uM) although there was a tendency to reduce the 
effect of anadamide by AM630. AM630 alone had no significant effect on the number of 
neurons/ganglion in the presence of araC (Figure 26). AM630 (1uM) was also not able to 
significantly inhibit the effect of anandamide on the number of total neurons per well in 
the presence of araC (Figure 27). Although the effects of AM630 did not achieve 
statistical significance, they did revese the effects of anandamide at all but the highest 
concentration. These data suggested that CB2 receptors are likely to be involved in 
anandamide mediated neuronal death in absence of enteric glia. 
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Figure 24. Neurons in ganglia dose response to anandamide with CB1 antagonist in 
resence of araC. 
rimary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
and then treated with anandamide (1nM-10uM) in DMEM0 medium 
p
P
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC; 
10uM) for 3 days 
with araC for 4 days. Some cultures were treated additionally with the CB1 receptor 
antagonist AM251 (1uM) on day 3.The number of neurons in ganglia was counted on day 
7 after immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide (1nM-
0.1uM) decreased the number of neurons/ganglion by 15-20% in the presence of araC. 
This effect was partially reversed by CB1 antagonist, AM251 (1uM). Data was shown in 
doses 10nM and 10uM. Neuronal survival is expressed as percentage change from 
control. Values are means±SEM of 7 animals. * = P<0.05. 
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Figure 25. The Number of total neurons per well dose response to anandamide with CB1 
ntagonist in presence of araC. 
rimary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
ted with anandamide (1nM-10uM) in DMEM0 medium 
a
P
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC; 
10uM) for 3 days and then trea
with araC for 4 days. Some cultures were treated additionally with the CB1 receptor 
antagonist, AM251 (1uM) on day 3. The number of total neurons per well was counted 
on day 7 after immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide 
(1nM-10uM) decreased the number of total neurons per well by 13-66% in the presence 
of araC, which was partially blocked by AM251. AM251 did not significantly change the 
effect of anandamide at 10uM. Data was shown in doses 10nM and 10uM. Neuronal 
survival is expressed as percentage change from control. Values are means±SEM of 7 
animals. * = P<0.05. 
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Figure 26. Neurons in ganglia dose response to anandamide with CB2 antagonist AM630 
 presence of araC. 
rimary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
d then treated with anandamide (1nM-10uM) in DMEM0 medium 
in
P
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC; 
10uM) for 3 days an
with araC for 4 days. Some cultures were treated additionally with the CB2 receptor 
antagonist, AM630 (1uM) on day 3. The number of neurons in ganglia was counted on 
day 7 after immnuostained with neuronal marker anti-PGP9.5 antibody. Anandamide 
(1nM-0.1uM) decreased the number of neurons/ganglion by 17-30% in the presence of 
araC. This was partially blocked by AM630 (1uM). Data was shown in doses 10nM and 
10uM. Neuronal survival is expressed as percentage change from control. Values are 
means±SEM of 4 animals. * = P<0.05. 
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Figure 27. The Number of total neurons per well dose response to anandamide with CB2 
ntagonist AM630 in presence of araC  
rimary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
 anandamide (1nM-10uM) in DMEM0 medium 
a
P
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC; 
10uM) for 3 days and then treated with
with araC for 4 days. Some cultures were treated additionally with the CB2 receptor 
antagonist, AM630 (1uM) on day 3. The number of total neurons per well was counted 
on day 7 after immunostained with neuronal marker anti-PGP9.5 antibody. AM630 
(1uM) partially inhibit the effect of anandamide on neuronal death in the presence of 
araC. Data was shown in doses 10nM and 10uM. Neuronal survival is expressed as 
percentage change from control. Values are means±SEM of 4 animals. * = P<0.05. 
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could be mediated by CB1 and CB2 receptors. The inhibition by lowest levels of 
nadamide is most sensitive to the CB antagonists whereas the inhibition induced by the 
ighest level of anandamide is less sensitive. This data also demonstrates that the effect 
val, we examined 
e newly developed immorto fetal enteric neuronal cell line (IM-FEN). Phase contrast 
gree and differentiated to 
0uM) (Figure 30). While this is consistent 
a
h
of anandamide is highly dependent on whether glial are present or absent from the 
cultures and suggests that glial may respond to cannabinoids and alter the overall effect 
of anandamide. We examined this in later studies of this thesis project. 
 
Inhibition of enteric neuronal cell survival by anandamide  
To confirm the direct inhibitory effect of anandamide on neuronal survi
th
images confirmed that the enteric cell line proliferated at 33 de
form neurites at 39 degree (Figure 28). Consistent with the production of neurites, most 
of the cells expressed the neuronal marker PGP9.5 (Figure 29); this is consistant with the 
report by Dr. S. Srinivasan’s group at Emory University who supplied the cell line to us. 
In addition, this cell line was able to form ganglion-like structures and these structures 
further connected to the complicate networks.  
Anandamide treatment at 39 degree had no effect on the number of total cells (Data not 
shown), however, it decreased neuronal cell percentage in a concentration-dependent 
manner (11-45% decrease in survival at 1nM-1
with the effect of anandamide to inhibit neuronal survival in primary cultures as 
described above, the effect in the cell line could be due to the neuronal cell death or 
differentiation to non-neuronal cells or both.  
To partly address this question, we treated the cells with anandamide at 33 degree to  
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Figure 28. Phase contrast images of enteric cell line cultured at 33 and 39 degree. 
ells was proliferated at 33 degree, and after cultured at 39 degree for 7 days they began 
 differentiate with neurites. 
C
to
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Figure 29. Neuronal marker PGP9.5 expression in enteric neuronal cell line (IM-FEN). 
he cells were cultured in 33 degree for 2-3 days and then grown at 39 degree for 7 days. 
munofluoresence staining was performed with anti-PGP9.5 antibody and image was 
l 
T
Im
shown in right panel. Most of cells expressed neuronal marker PGP9.5. Negative contro
was shown in left panel. 
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Figure 30. Anandamide dose response curve for enteric neuronal cell line at 39 degree. 
nteric neuronal cell line (IM-FEN) was cultured in 33 degree for 2-3 days and then 
ove to 39 degree treated with anandamide (1nM-10uM) in neural basal A medium for 7 
al 
E
m
days. The medium was changed once on day 3. The effect of anandamide on neuron
survival was measured by counting cells immunostained with anti-PGP9.5 antibody. 
Anandamide treatment at 39 degree decreased neuronal cells percentage in a 
concentration-dependent manner (11-45% decrease in survival at 1nM-10uM). The 
number of total cells had no significant change among groups (Data not shown). 
Neuronal survival is expressed as percentage change of PGP9.5-positive cells in total 
cells. Values are mean ±SEM of 4 experiments. * = P<0.05. 
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eliminate the effect of anandamide on cell differentiation at 39 degree. Anandamide also 
ecreased neuronal survival in a concentration-dependent manner at 33 degree (10-22% 
ecrease in survival at 1nM-10uM) (Figure 31). This further support the idea that 
uld reverse 
nandamide-decreased neuronal survival. This question was based on the findings in 
amide. Getting 
B2 receptors in enteric glia 
 inhibit survival. Anandamide also inhibited neuronal survival in absence of enteric glia 
which could be mediated by CB1 and CB2 receptors and inhibited the enteric neuronal  
d
d
anandamide could inhibit neuronal survival in this enteric neuronal cell line. 
 
Effect of anandamide on cocultures of enteric cell line and astrocytes 
Next we want to know whether co-culture enteric cell line with glia co
a
primary cultures where the presence of glia altered the effect of anand
enough of primary enteric glia takes a very long time (months are required to obtain a 
few coverslips) because these cells divide very slowly. To address this question in some 
manner, we used a commercially available astrocyte cell line, which was isolated from 
mice brain. Astrocytes were chosed becasue the enteric glial cells are most closely related 
to astrocytes. At the time of these studies, enteric glial cells were not available 
commercially.  Unfortunately, this cell line was not able to inhibit anandamide-induced 
neuronal cell death (Figure 32). This lack of effect is likely due to the fact that the cells 
were not truly enteric glial cells and there neither supports or rejects our hypothesis 
relative to the role of glial cells in the response to andamide. 
 
Taken together with previous data, it illustrated that anandamide may act on CB1 
receptors in enteric glia to promote ganglia survival and on C
to
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Figure 31. Anandamide dose response curve for enteric neuronal cell line at 33 degree.  
Enteric neuronal cell line (IM-FEN) was cultured in 33 degree treated with anandamide 
(1nM-10uM) in DMEM/F12 medium for 2-3 days and then moved to 39 degree without 
anandamide teatment for 7 days. The medium was changed once on day 3. The effect of 
h 
 
anandamide on neuronal survival was measured by counting cells immunostained wit
PGP9.5. Anandamide decreased neuronal survival in a concentration-dependent manner 
at 33 degree. (10-22% decrease in survival at 1nM-10uM). Neuronal survival is 
expressed as percentage change of PGP9.5-positive cells in total cells. Values are mean 
±SEM of 3 experiments. * = P<0.05. 
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Figure 32. Anandamide dose response curve for enteric neuronal cell line cocultured with 
astrocyte cell line at 39 degree.  
Enteric neuronal cell line (IM-FEN) was co-cultured with astrocyte cell line at 33 degree 
in DMEM/F12 medium for 2-3 days and then moved to 39 degree treated with 
ct of anandamide on neuronal survival was measured by 
 
anandamide (1nM-10uM) in neural basal A medium for 7 days. The medium was 
changed once on day 3. The effe
counting cells immunostained with anti-PGP9.5 antibody. The astrocyte cell line was not 
able to inhibit anandamide-induced neuronal cell death. Neuronal survival is expressed as 
percentage change of PGP9.5-positive cells in total cells. Values are mean ±SEM of 3 
experiments. * = P<0.05. 
 
 
 
 
 
 
 
105 
 
 
 
 
 
 
 
 
 
 
 
 
 
* *
**0 -9 -7 -5-60
-50
-40
-30
-20
-10
0
10
ECL ALONE
ASTRO + ECL
%
 o
f n
eu
ro
na
l c
el
ls
Anandamide log(M)
 
106 
cell line in both 33 and 39 degrees. 
 
CB1 and CB2 expression in primary cultu onal cell line 
Immunofluoresence staining showed that CB1 receptors are not only expressed in enteric 
lls in primary cultures. However, enteric glia CB1 
xpression is lower than in enteric neurons. Interestingly, enteric glia cells with 
es spread 
teric neuronal cell line, which were 
ot shown) 
bsence of araC). We 
sted the MAPK pathway, PLC-beta pathway and PI3K/AKT pathway by using their 
ide increased the 
res and enteric neur
neurons but also in enteric glia ce
e
concentrated cell bodies had strong S100 and CB1 staining and when cell bodi
out, the staining density became lower (Figure 33). 
CB2 receptors are also expressed in both enteric neurons and glia cells in primary 
cultures. There are similar staining densities between neurons and glia. CB2 expression 
was evenly distributed in the glia cell body (Figure 34).  
Both CB1 and CB2 receptors were expressed in en
supported by immunofluoresence staining (Figure 35) and western blot results (Figure 
36). The protein extractions from spleen tissue of guinea pig and mice were used as a 
positive control in western blot for CB2 antibody. (Data n
 
Anandamide activated downstream signaling pathways in ganglia 
Next, we want to know which downstream signaling pathway(s) was involved in 
anandamide mediated ganglia survival in the presence of glial (i.e.,a
te
inhibitors. The results are shown in Figure 37. Again, 0.1uM anandam
ganglia survival in absence of araC. The PLC-beta inhibitor U73122 (1uM) alone had no 
significant effect on the ganglia survival (Data not shown), however, it inhibited  
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Figure 33. CB1 expression in primary cultures of enteric ganglia 
rimary cultures of enteric ganglia were prepared from guinea pig intestine and grown in 
MEM10 medium for 7 days. CB1 receptor expression was determined by 
munofluoresence co-staining anti-CB1 antibody with neuronal marker PGP9.5 or glia 
rons but also in enteric 
P
D
im
marker S100. CB1 receptors are not only expressed in enteric neu
glia cells in primary cultures. Middle left: PGP9.5 (green), middle right: CB1 (red), 
bottom left: S100 (green), bottom right: CB1 (red). Negative controls are shown in top 
two. Arrows indicate examples of positive staining for enteric neurons. Arrowheads 
indicate examples of positive staining for enteric glia. 
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Figure 34. CB2 expression in primary cultures of enteric ganglia 
rimary cultures of enteric ganglia were prepared from guinea pig intestine and grown in 
MEM10 medium for 7 days. CB2 receptor expression was determined by 
munofluoresence co-staining anti-CB2 antibody with neuronal marker PGP9.5 or glia 
urons and glia cells in 
P
D
im
marker S100. CB2 receptors are expressed both in enteric ne
primary cultures. Top left: PGP9.5 (green), top right: CB2 (red), bottom left: S100 
(green), bottom right: CB2 (red). Arrows indicate examples of positive staining for 
enteric neurons. Arrowheads indicate examples of positive staining for enteric glia. 
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Figure 35. CB1 and CB2 receptors expression in enteric neuronal cell line (IM-FEN) by 
munocytochemistry. 
he cells were cultured in 33 degree for 2-3 days and then grown at 39 degree for 7 days. 
munofluoresence staining was performed with anti-CB1 or anti-CB2 antibodies and 
ronal cell line. 
im
T
Im
images were shown in left and right side respectively. Both CB1 and CB2 receptors were 
expressed in enteric neu
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Figure 36. CB1 and CB2 receptors expression in enteric neuronal cell line (IM-FEN) 
he cells were cultured in 33 degree for 2-3 days and then grown at 39 degree for 7 days. 
rotein extracts were immunobloted with either anti-CB1 or anti-CB2 antibodies and 
B1 (60 KDa) and CB2 (38 KDa) bands are shown. Both CB1 and CB2 receptors were 
T
P
C
expressed in enteric neuronal cell line. Protein markers were shown in left side. 
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Figure 37. Anandamide mediated downstream signaling pathway 
rimary cultures of enteric ganglia were prepared from guinea pig intestine. Each well 
as seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with 
nandamide (0.1uM) in DMEM0 medium for 4 days. Some cultures were treated 
hibitor U73122 (1uM), 
P
w
a
additionally with the MAPK inhibitor PD98059 (1uM), PLC in
and PI3K inhibitor LY-294002 (1uM) on day 3. The number of ganglia was counted on 
day 7 after immunostained with neuronal marker anti-PGP9.5 antibody. Again, 0.1uM 
anandamide increased the ganglia survival in absence of araC. PLC inhibitor U73122 
(1uM) alone had no significant effect on the ganglia survival (data not shown); however, 
it inhibited anandamide induced ganglia survival significantly. PD98059 and LY-294002 
also inhibited anandamide induced ganglia survival, although not significantly. 
Ganglionic survival is expressed as percentage change from control. Values are 
means±SEM of 6 animals. * = P<0.05. 
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anandamide induced ganglia survival significantly, suggesting the effect of anandamide 
n promoting ganglia survival is mainly mediated by PLC pathway. A role of MAPK and 
I3K/AKT is less well supported since antagonists of these pathways caused slight but 
 the enteric neural cell line (IM-FEN), we tested the downstream signaling pathways 
ive antagonists. Firstly, we treated the enteric cell line with MAPK, PLC-beta, and 
o
P
nonsignificant inhibition of the effects of anandamide. We were not able to measure the 
anandamide downstream pathways by western blot in that this is a complex of enteric 
neurons and glia. 
 
Anandamide activated downstream signaling pathways in the enteric neural cell 
line. 
In
involved in anandamide mediated enteric neuronal death by western blot and use of the 
select
PI3K inhibitors and examined the total cell survival. The PLC-beta inhibitor U73122 
(10uM) decreased the total cells by nearly 40% (Figure 38), which made us unable to 
examine the effect of this compound on the neuronal percentage further. Next, we wanted 
to know whether the MAPK and PI3K inhibitors affect the anandamide mediated 
neuronal cell death. We used 10uM anandamide to inhibit the neuronal survival becasue 
the inhibition at this concentration was most significant. As shown in Figure 39, 
treatment with anandamide (10uM) and PD98059 (10uM) together increased 
anandamide-mediated inhibition up to 136%, suggesting that the MAPK pathway may 
protect the neuronal cells from anandamide induced death. In contrast, combination of 
anandamide (10uM) and LY-294002 (10uM) decreased anandamide-mediated inhibition 
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down to 35%, suggesting PI3K could mediate the inhibition of anandamide on neuronal 
percentage. 
 
 
Figure 38. Effect of MAPK, PLC and PI3K inhibitors on the number of total cells at 39 
degree 
to 39 degree treated with MAPK inhibitor PD98059 (10uM), PLC inhibitor 
 
 
 
 
 
 
Enteric neuronal cell line (IM-FEN) was cultured in 33 degree for 2-3 days and then 
moved 
U73122 (10uM), or PI3K inhibitor LY-294002 (10uM) in neural basal A medium for 7 
days. The medium was changed once on day 3. The effect of MAPK, PLC and PI3K 
inhibitors on the number of total enteric cell line was counted. U73122 (10uM) treatment 
at 39 degree decreased the number of total cells nearly 40%. Values are mean ±SEM of 3 
experiments. * = P<0.05. 
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Figure 39. Effect of MAPK and PI3K inhibitors on the percentage of neuronal cells at 39 
degree 
 39 degree treated with 10uM anandamide and MAPK inhibitor PD98059 (10uM) 
 
Enteric neuronal cell line (IM-FEN) was cultured in 33 degree for 2-3 days and then 
move to
or PI3K inhibitor LY-294002 (10uM) in neural basal A medium for 7 days. The medium 
was changed once on day 3. The effect on neuronal survival was measured by counting 
cells immunostained with anti-PGP9.5 antibody. The inhibition of 10uM anandamide in 
neuronal survival was normalized as 100. Treatment with anandamide (10uM) and 
PD98059 (10uM) together increased anandamide-mediated inhibition up to 136%, 
suggesting MAPK may protect the neuronal cells from anandamide induced death. 
Treatment with anandamide (10uM) and LY-294002 (10uM) together decreased the 
inhibition down to 35%, suggesting PI3K could mediate the inhibition of anandamide on 
neuronal percentage. Neuronal survival is expressed as percentage change of PGP9.5-
positive cells in total cells. Values are mean ±SEM of 3 experiments.  
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We further tested whether anandamide treatment altered the expression of p-MAPK and 
p-AKT by western blot. The representative bands of p-MAPK were shown in Figure 40. 
The quantitative results showed the expression of phospho-P44/42MAPK level was 
 
increased by 13-48% after treatment with anandmide. MAPK activation was increased 
most (48% increase) with 1nM anandamide treatment, and then this increase became less 
(36% and 13% increase, respectively) with anandamide up to 0.1uM and 10uM (Figure 
41). The representative bands of p-AKT were shown in Figure 42. The quantitative 
results showed the expression of p-AKT level was dose-dependently increased with 
anandamide treatment (1nM-10uM) (Figure 43). These data support the idea mentioned 
earlier (see Figure 34) that MAPK and PI3K/AKT pathways were involved in 
anandamide-mediated inhibition of neuronal survival. We further compared the 
anandamide-induced change in p-MAPK and p-AKT with the anandamide induced 
inhibition in neuronal percentage. The curve of MAPK activation had a similar trend with 
the neuronal percentage inhibition and AKT activation was continually increased even 
when the neuronal percentage was decreased (Figure 44). The two curves crossed at 
around 1uM anandamide. These data suggested that the ratio of p-MAPK and p-AKT (i.e. 
the increasing p-AKT and the decreasing p-MAPK with increasing anandamide 
concentration) could be the cause of the anandamide-mediated inhibition in neuronal 
survival.  
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Figure 40. Representative western blots of P-P42/44MAPK from enteric neuronal cell 
ne treated with anandamide.  
nteric neuronal cell line (IM-FEN) was cultured in 33 degree for 2-3 days and then 
oved to 39 degree treated with anandamide (1nM-10uM) in neural basal A medium for 
e was striped and rebloted for P42/44 MAPK as control. 
li
E
m
7 days. The medium was changed once on day 3. The cell lysate was immunobloted for 
P-P42/44MAPK. The membran
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Figure 41. Quantitative analysis of phosphorylation of P42/44MAPK. 
he band intensities were quantitated by odyssey software and the ratio of P-
42/44MAPK to P42/44MAPK was calculated as expression of phospho-P42/44MAPK. 
he expression of phospho-P44/42MAPK level was increased by 13-48% after treatment 
 48% with 1nM 
T
P
T
with anandmide (1nM-10uM). MAPK activation was increased by
anandamide treament, and then this increase was less (36% and 13%, respectively) with 
increasing anandamide concentration to 0.1uM and 10uM. Values are relative changes 
compared with control and expressed as mean±SEM of 5 experiments. * = P<0.05. 
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Figure 42. Representative western blots of P-AKT from enteric neuronal cell line treated 
ith anandamide. 
nteric neuronal cell line (IM-FEN) was cultured in 33 degree for 2-3 days and then 
oved to 39 degree treated with anandamide (1nM-10uM) in neural basal A medium for 
rane was stripped and reblotted for total AKT as control. 
w
E
m
7 days. The medium was changed once on day 3. Protein extract was immunobloted for 
P-AKT. The memb
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Figure 43. Quantitative analysis of P-AKT 
he band intensities were quantitated by odyssey software and the ratio of P-AKT to 
KT was calculated as expression of P-AKT. P-AKT level was dose-dependently 
creased with anandamide (1nM-10uM) treatment. Values are relative changes 
an±SEM of 3 experiments. 
T
A
in
compared with control and expressed as me
 
 
 
 
 
 
 
 
 
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 -9 -7 -5
0.0
0.2
0.4
0.6
1.4
1.2
1.0
0.8
ve
 le
ve
l
* 
Anandamide log(M)
R
el
at
i
 
131 
 
 
 
 
 
 
 
 
 
Figure 44. Comparison of MAPK and AKT signalings with the inhibition of neuronal 
urvival by anandamide 
he curve of MAPK activation had a similar trend with the neuronal percentage after 
nandamide treatment. AKT activation was continually increased even when the neuronal 
atio of p-MAPK and p-AKT could be related to anandamide-
s
T
a
percentage was decreased. The two curves crossed at around 1uM anandamide. These 
data suggested that the r
mediated inhibition on neuronal survival. 
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Discussion 
 
Expression of CB1 in myenteric neurons and glia 
The enteric ganglion is composed of both neurons and glia. The expression of CB1 
receptors by enteric neurons has been well characterized (79-83,85,87,88). However, 
their expression by enteric glia is not clear, although there is ample evidence that they 
were present in astrocytes (140-144), microglial cells (91,145-152) and oligodendrocytes 
of the central nervous system (149). Here we show that CB1 receptors are not only 
expressed in enteric neurons but also in enteric glia in primary cultures of myenteric 
ganglia from guinea pig, which can play a relevant role in anandamide mediated 
ganglionic survival. 
Anandamide promotes ganglionic and neuronal survival in presence of enteric glia 
In the present study, the effect of anandamide and cannabinoid receptors on primary 
cultures of myenteric ganglia and neuron survival was summarized in Table 4. 
The effect of cannabinoids on neuronal survival has been studied by many groups, 
however, the results are controversial varying from neuroprotection (128-132) to 
neurotoxity (133-134). Cannabinoid neuroprotection is usually more evident in whole-
animal than in cultured-neuron models, which may result from their impact on various 
brain cell types (neurons, glia, vascular endothelium (153). In the present study, we have 
shown that anandamide increased neuronal survival through promoting the ganglionic 
survival in presence of glia, and that this effect is mediated by CB1 receptor.  
133 
134 
 
 
 
 
 
 
 
 
 
 
Table 4. The effect of anandamide and cannabinoid receptors in primary cultures of 
myenteric ganglia and neuron survival 
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  Ganglia survival Neuron/ganglia 
survival 
Total neuron/well 
survival 
Anandamide 
(AEA) 
+ glia 
 
Biphasic; 
Promoting ganglia 
survival at 1nM-
0.1uM; 
Inhibiting ganglia 
survival at 10uM 
No effect Promoting total 
neuron survival at 
1nM-0.1uM 
CB1 activation + glia Mediate AEA-
induced promoting 
ganglia survival 
No effect Mediate AEA 
induced promoting 
neuron survival 
CB2 activation + glia Mediate 10uM 
AEA-induced 
inhibiting ganglia 
survival 
Inhibition of 
neuron/ganglion 
survival 
Mediate 10uM 
AEA induced 
inhibition of 
neuron survival  
TRPV1 + glia No effect Not tested Not tested 
Anandamide 
(AEA) 
- glia Inhibition of 
ganglia survival at 
10uM 
Inhibition of 
neuron/ganglion 
survival 
Inhibition of total 
neuron survival at 
10uM 
CB1 - glia No effect Partially mediate 
AEA induced 
inhibition of 
neuron survival  
No effect 
CB2 - glia Partially mediate 
10uM AEA-
induced inhibiting 
ganglia survival 
Partially mediate 
AEA induced 
inhibition of 
neuron survival 
Partially mediate 
10uM AEA 
induced inhibition 
of neuron survival 
TRPV1 - glia Not tested Not tested Not tested 
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This clearly suggested glia could play an indispensable role in cannabinoid-mediated 
neuroprotection. However, the exact mechanism is still not clear. Some studies have 
shown that cannabinoids protect glial cells from ceramide induced apoptosis in vivo and 
in vitro (154) and from oxidative stress damage through CB1 receptors (155). In addition, 
CB1 receptor-mediated neuroprotection might result from cross-talk to the growth factor 
system. For example, chronic exposure to Δ9-THC up-regulated brain derived 
neurotrophic factor (BDNF) in specific brain areas in vivo (156) and BDNF is known to 
be involved in CB1 receptor-dependent protection against excitotoxicity (157). Thus, 
anandamide could protect enteric glia from death thereby maintaining the ganglia 
integrity and also transactivate the tyrosine kinase receptors to protect ganglionic and 
neuronal survival. 
Anandamide promotes ganglionic survival through CB1 and PLC-beta primarily 
CB1 receptors are G protein-coupled seven-transmembrane receptors (GPCR) (158). 
They are preferentially coupled to PTX-sensitive Gi/o proteins (33-34). Recently some 
studies showed they could also couple to Gq/11 proteins (144,159-160). Activation of 
CB1 receptors can activate PLC-beta in a PTX-sensitive manner mediated by the Gi/o βγ 
subunits (161-163) or PTX-insensitive manner mediated by the Gq/11 (144,159-160). In 
the present study, we show that anandamide mediated ganglionic survival was blocked by 
the PLC-beta inhibitor U73122, suggesting this effect was mediated by the PLC-beta 
pathway. However, whether it is Gi/o or Gq/11 mediated has not been tested yet. 
Context-specific activation of G proteins could partially explain the complexity of 
cannabinoid effect in the nervous system. In addition, it is not completely clear where 
activation exactly happens: enteric neurons or glia. Some studies suggest that the 
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cannabinoid agonist WIN 55212-2 could activate the CB1 receptor in astrocytes directly 
to induce Ca2+ elevation through activation of PLC-beta (144). Our studies also suggest 
that there may be a possibility that the effect of cannabinoids on ganglionic survival 
activates the MAPK and PI-3K/AKT pathways but to a lesser extent than the PLC-beta 
pathway. Using the selective antagonists of these pathways, we found a tendency to 
decrease ganglionic survival although this decrease did not achieve statistical 
significance.  
CB2 expression in enteric neurons and glia 
The CB2 receptor was originally found in immune cells, where one of its roles being to 
modulate cytokine release (49). Later it was detected morphologically and functionally in 
neurons in central nervous system (164) and enteric nervous system (89). In the present 
study, we also show that CB2 receptors are expressed in enteric neurons in primary 
cultures of myenteric ganglia from guinea pig. In addition, we found that enteric glia 
expresses CB2 in this culture condition as well. This is in contrast with other studies, 
which did not observe CB2 receptor expression on enteric glia under normal conditions 
and in the LPS-treated tissues for 2 hours in whole mount preparations of the rat 
myenteric plexus (89). This difference could be explained in several ways. It could be 
that CB2 expression was inducible in enteric glia by culturing up to 7 days. In this point, 
enteric glia could have certain microglial properties. Since studies have shown that 
microglial cells in primary cultures are intrinsically activated or “primed” because of the 
procedures involved in transferring these cells into culture (165) and primed microglia 
prepared from human, rat or mouse tissue express CB2 receptors (91,146-148,166-168). 
It could also be that our primary cultures have the advantage that glia cells spread out and 
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attach to the bottom of wells instead of wrapping together with neurons and ganglia, as 
they would in the whole mount preparations, thus providing increased access to 
immunostaining and visualization of the CB2 staining. In addition, it could be a species 
difference in that our stuidies were done in guinea pig whereas the other studies were 
done in rat whole mounts.   
Enteric glia were found in enteric ganglia, the interconnecting nerve strands of the 
ganglionated plexuses (14). Subsequently, enteric glia bodies and processes were clearly 
demonstrated within the mucosal plexus (15-17), and glial processes make close contacts 
with the epithelial cell layer (15,17-20). Interestingly, CB2 immunoreactivity was 
detected in the epithelium of colonic tissue from inflammatory bowel disease (88). This 
suggests a role for this receptor in inflammation, although whether it is expressed by 
enteric glia in mucosal plexus have not been tested. 
Role of CB2 in myenteric ganglionic survival 
Activation of CB2 receptors has been implicated to be actively involved in the gut 
response to inflammation including decreasing motility (111) and inhibiting local 
histological damage (112). In addition, activation of CB2 receptors reduced the basal 
sensitivity and the TNBS colitis-induced hypersenstitivity to colorectal distension in rats 
(115) and inhibited the endogenous immunogenic agent bradykinin response in murine 
mesenteric afferent nerve activity (169).  
There are few data about the role of CB2 receptors in astrocytes and most studies about 
CB2 function in glia came from microglial cells involving an anti-inflammatory role. (For 
review, see 168). Studies have shown that stimulation of CB2 receptors by 2-AG 
increases Erk activity in monocytes and increases migration of monocytes (73,170-172). 
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CB2 receptor activation decreases the in vitro production of proinflammatory molecules 
in rat microglial cells (147, 173), and human microglial and THP-1 cells (174). More 
recently the studies show that activation of CB2 receptors by 10uM anandamide inhibits 
LPS/IFNγ-induced production of IL-12 (p35/40) and IL-23 (p19/p40) through ERK1/2 
and JNK pathways in microglial cells (175). Stimulation of CB2 receptors by 2-AG also 
increases microglial cell proliferation (176). However, in the present study we found that 
anandamide decreased ganglia survival at high concentration (10uM), and this effect 
appeared to be mediated by CB2 receptors; suggesting activation of CB2 receptors could 
induce ganglia death. Our data appears to be contradictory to the results mentioned 
above. In our primary ganglia system where enteric neurons and enteric glia coexist, 
neuron-glia communication is an important factor for mediating ganglia survival. This is 
a very different relationship and is different from the studies utilizing the microglial cell 
line (176). Another possible reason for the difference could be due to the different 
agonists used. Anandamide acts as a partial agonist while 2-AG functions as a full agonist 
for CB2. Moreover, the agonistic activity of 2-AG was attenuated by anandamide (177). 
Both anandamide (0.036 nmol/g tissue) and 2-AG (44 nmol/g tissue) are found in the gut 
(110), and understanding how these two endogenous agonists modulate CB2 receptors 
could be important for elucidating the mechanisms of endocannabinoid in gut 
inflammatory diseases. It is important to note too that we find different effect of 
anandamide depending on the concentration. It is not known whether in physiological or 
pathological conditions, the local concentration of anandamide could be up to the 10uM 
level necessary to activate CB2 receptors. 
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Role of CB2 in enteric neuronal survival 
It has been proposed that activation of CB2 receptors is neuroprotective (see review 178). 
CB2 receptors were up regulated or inducible after pathological neuroinflammatory 
insults and activation of CB2 receptors provided neuroprotection in neurodegenerative 
disorders such as Alzheimer’s disease (AD), Huntington’s disease (HD), amyotrophic 
lateral sclerosis (ALS) and multiple sclerosis (MS). These effects have been shown to be 
mainly through a series of glia-dependent anti-inflammatory actions. For example, 
activation of CB2 receptors also reduces the release of proinflammatory factors including 
nitric oxide, TNFα, IL-1 and IL-6 in animal models of perinatal hypoxia–ischaemia (179) 
and Huntington's disease (180). However, a recent study has shown in vivo and in vitro 
that the exogenous cannabinoids delta-9-tetrahydrocannabinol and CP55940 inhibit the 
chemotactic response of microglia to Acanthamoeba culbertsoni, an opportunistic 
pathogen that is the causative agent of Granulomatous Amoebic Encephalitis, through 
activation of the CB2 receptors (181,182). In the present study, we have shown that 
AM630 significantly promote the neuronal survival in ganglia by 35% when treatment 
together with anandamide (0.1uM) in the presence of glia. AM630 alone tended to 
increase neuronal survival in ganglia as well. These data suggest that activation of CB2 
receptors could decrease neuronal survival in the presence of glia. Since 0.1uM 
anandamide, would be too low to activate CB2 receptors, our data suggests there is an 
endogenous tone of endocannabinoids to activate CB2 receptors to decrease the neuronal 
survival in the primary cultures of ganglia. This may be mediated by release of 
endogenous 2-AG.which is a preferential agonist of the CB2 receptor. This possibility 
could be tested in future studies.  
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Anandamide inhibits enteric neuronal survival in absence of enteric glia 
Anandamide has also been reported to induce cell death in rat cortical neuronal cultures 
(134). In addition, Δ9-THC had a neurodegenerative effect in cultured cortical neurons as 
well and it appeared to involve the CB1 receptor (133,135). In the present study, we show 
that anandamide (1nM-0.1uM) inhibit neuronal survival in the absence of glial cells (i.e. 
presence of araC). This effect was partially reversed by CB1 antagonist, AM251 (1uM) 
and by the CB2 antagonist AM630. This suggests that the anandamide induced decrease 
in neuronal survival without enteric glia cells, could be mediated by both the CB1 and 
CB2 receptors. To confirm the direct effect of anandamide on neurons, next we looked at 
the newly developed immorto fetal enteric neuronal cell line (IM-FEN). Anandamide 
decreased the percentage of neuronal cells in a concentration-dependent manner at both 
39 and 33 degree. This further supports the idea that anandamide could inhibit survival of 
the neuronal cells.  
Anandamide mediated pathways in enteric neuronal cell line 
We also found that anandamide increased the expression of phospho-P44/42MAPK in the 
enteric neuronal cell line although the lowest concentrations of andamide caused the most 
increase in P-MAPK.  As the concentration of anandamide increased, the stimulation of 
p-MAPK decreased and the percentage of neuronal survival also decreased.  This 
suggests that anadamide may have a dual effect on MAPK and that MAPK may have a 
protective effect on neuronal suvival. Thus increasing levels of anandamide decrease the 
stimulation of p-MAPK leading to decrease protection from cell death. Cannabinoids 
mediated MAPK activation has previously been reported in the rat cerebral frontal cortex 
(183), the dorsal striatum and the nucleus accumbens (NA) (184) and Neuro2a cells 
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(185). A role for cannabinoids-induced apoptosis involved MAPK has also been 
demonstrated previously in leukemic cell lines (186) and human breast cancer cells (187). 
The previous studies also showed that the tumour suppressor protein, P53 (135), and 
Calpain (134) were involved in the cannabinoids-mediated cell death in cultured cortical 
neurons. However, whether these were related to MAPK has not been tested yet. Our 
studies also demonstrated that anandamide increased levels of p-AKT and that increasing 
levels of anandamide led to increased levels of p-AKT.  Thus, the levels of p-AKT 
paralleled the increased neuronal death as the concentration of anandamide increased. 
This pattern is the exact opposite to that described for p-MAPK. Thus, it may be that 
rising p-AKT levels and falling p-MAPK levels and or changes in the ratio of these signal 
pathways may be the cause of the neuronal cell death caused by increasing levels of 
anandamide. This would be an area for future investigations. We should note for 
completeness that we also tested the PLC-beta antagonist, U73122. This agent caused a 
decrease in the total number of cells (both neural and non-neural cells) in the cultures. 
This effect prevented us from examining the role of PLC-beta in these IM-FEN cultures 
and we therefore did not examine whether or not anandaminde caused the production of 
PLC-beta in these cells. This leaves open the possibility of an additional role of this 
signaling pathway in mediating the effects of anandamide. 
Role of TRPV1 in myenteric ganglionic survival 
It is well known that sensory neurons express TRPV1 receptor. The previous studies have 
shown that endocannabinoids stimulate intestinal sensory neurons via the TRPV1 to 
release SP, resulting in ileitis in rats (108). In addition, the TRPV1 antagonist 
capsazepine (10-5M) inhibited neuropeptide release, including somatostatin, substance P, 
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and CGRP, from isolated rat tracheae induced by high concentrations of anandamide (5x 
10-5M, 10-4M) (188). However, TRPV1 receptors have not been found in the enteric glia 
cell so far. In the present study, we found that both the stimulating and inhibiting effects 
of anandamide on ganglionic survival were not inhibited by the TRPV1 antagonist 
capsazepine, suggesting TRPV1 receptor may not play a role in anandamide-mediated 
ganglia survival. This could be due to the suggestion that TRPV1 was not expressed in 
enteric glia and had little effect on enteric glia survival.  
Formation of networks in enteric neuronal cell line 
Nerves of the enteric nervous system derive from migratory vagal neural crest cells and 
sacral neural crest cells, which enter the foregut at embryonic day (E) 9-9.5 in mice and 
reach the terminal colon by E14 to E15 (see review 189). The fetal enteric neuronal cell 
line (IM-FEN) was isolated from the intestines of E13 immortomice (H-2Kb-tsA58 
transgenic mice) fetuses using p75NTR antibody to separate out neural precursor cells 
(139). Previous studies have shown that bone morphogenetic protein (BMP) is necessary 
for neural crest cell migration and ganglion formation in the enteric nervous system in 
chick (190). In the present study we found that this cell line was able to form ganglion-
like structures and these structures further interconnected to form complicated networks. 
To form this network, the cells need proliferate to 100% confluence so that they can be 
very close to each other. This phenomenon can be observed both in 33 and 39 degrees, 
suggesting they have this ability even without differentiation in 39 degree. We also 
observed that the surrounding cells tended to move toward to the center of ganglion-
structure. This implies that there are certain signaling molecules produced by the cells 
that act as a chemoattractant to induce this movement. Interestingly, the cells in the core 
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of this structure stain positive for PGP9.5, suggesting that the chemoattractant derives 
from the neuronal cells, but not others. This is also supported by our studies in coculture 
enteric neuronal cell line with the astrocyte cell line. We found that the astrocyte cell line 
alone was not able to form this ganglion-like structure even though they are 100% 
confluent, however, the ganglion-like structures and network formed when they were 
cocultured together with enteric neuronal cell line. This observation suggest that this 
function in vitro could mimic the process of enteric nervous system development in vivo 
and could be a good model for studying the ganglia colonization and the mechanisms of 
Hirschsprung’s disease. It also suggest that our studies of the effects and mechanims of 
action of cannabinoids in the IM-FEN cell line are a good model for the actions of 
cannabinoids in the studies of primary ganglia isolated from the guinea pig intestine. 
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